DALE ERIC BREDESEN
CURRICULUM VITAE

EDUCATION

9/70-6/74	California Institute of Technology	B.S. Biology and Literature, 1974
8/74-12/77	Duke University Medical Center Durham, North Carolina	M.D. 1977
6/78-7/80	Duke University Medical Center	Resident, Medicine
7/80-6/83	University of California San Francisco, California	Resident, Neurology Chief Resident
7/83-6/87	University of California San Francisco, California	Clinical Instructor Neurology
1/85-1/86	Laboratory of Dr. LY Jan (Drosophila Neurogenetics) Howard Hughes Medical Institute San Francisco, California	Hughes Associate
2/86-6/89	Laboratory of Dr. SB Prusiner (Neurodegenerative Disease) University of California San Francisco, California	NIH Postdoctoral Fellow
LICENSURE	45163	Issued: 07/02/1981; Exp 06/30/1995

BOARD CERTIFICATION American Board of Neurology and Psychiatry, 1986

PROFESSIONAL EXPERIENCE:

Previous Positions held:

Augustus Rose Professor of Neurology
Director, Mary S. Easton Center for
Alzheimer's Disease Research at UCLA
Director, Alzheimer's Disease Program
Director, Neurodegenerative Disease Research
David Geffen School of Medicine at UCLA

7/87-2/89	UCSF, Department of Neurology	Assistant Adjunct Professor
3/89-6/94	UCLA, Department of Neurology	Assistant Professor
7/94-6/95	UCLA, Department of Neurology	Associate Professor
4/93-6/95	UCLA, Center on Aging	Elizabeth R. and Thomas E. Plott Chair
11/94-6/99	The Burnham Institute	Professor and Director, Program on Aging
7/95-6/97	UCLA, Department of Neurology	Associate Adjunct Professor
9/96-6/98	Neuroscience Department, UCSD	Associate Adjunct Professor
7/98-7/00	Neuroscience Department, UCSD	Adjunct Professor
7/99-7/05	The Burnham Institute	Adjunct Professor
7/99-7/05	Buck Institute for Age Research	President and CEO
9/99-present	UCSF	Adjunct Professor
7/05-7/06	Buck Institute for Age Research	Scientific Director and CEO
7/06-4/08	Buck Institute for Age Research	Director and CEO

4/08-12/13	Buck Institute for Age Research	Professor and Founding President/CEO
2008 – Present	Dominican University, San Rafael, CA	Honorary Professor
12/13 - Present	Buck Institute for Research on Aging	Professor (Emeritus 7/17-present)
	Professor, UCLA Dept. of Neurology	

PROFESSIONAL ACTIVITIES

Memberships:	Society for Neuroscience
	American Society for Biochemistry and Molecular Biology (ASBMB)
	American Academy of Neurology
2014	Editorial Board member, Brain and Gut Journal
2013	Contributing Member, f1000 Prime
2013	Member, CPMC Brain Health Advisory Committee
2012	Scientific Advisory Board, Reckitt Benckiser
2011	Associate Editor, J Alzheimer's Disease
2010	Editorial Board Member, Journal of Biological Chemistry
2009	UCSF Hellman External Advisory Board member
2008	Member, National Advisory Council on Aging – National Institute on Aging
2008	Board of Directors, Burke Rehabilitation Hospital
2008	Scientific Advisory Board, Gladstone Institute for Neurological Disease
2006	Academic Board Review Member, Ernest Gallo Clinic and Research Center
2000	Consultant, Idun Pharmaceutical

2000	Consultant, Neurex Corporation
2000	Consultant, Mitokor Corporation
1996	Lou and Eleanor Gehrig Lectureship, Columbia University (given for the most outstanding work on amyotrophic lateral sclerosis within the previous year)
1996	Child Neurology Society Lectureship
1993-95	Elizabeth R. and Thomas E. Plott Chair in Gerontology, UCLA
1982-83	Chief Resident, Neurology, UCSF
1973	NSF Summer Fellow, Caltech (Dr. R. Sperry, Psychobiology)
1972	Member, Board of Control, Caltech
1972	Research Assistant, MIT (Dr. M. Wrighton, Inorg. Chemistry)
1971	Research Assistant, Caltech (Dr. H. Gray, Inorg. Chemistry)

HONORS AND SPECIAL AWARDS

2005	Gilman-Barbour Distinguished Lecturer, University of Michigan
2000	Arthur Cherkin Award for Research in Neurodegenerative Disease, UCLA
1997	United Way Combined Health Agencies Health Hero (annual award for outstanding medical research in San Diego)
1996	Lou and Eleanor Gehrig Lectureship, Columbia University (given for the most outstanding work on amyotrophic lateral sclerosis within the previous year)
1992	Cotzias Award, American Parkinson Disease Foundation
1992	Honorable Mention, UCLA Neurology Residents' Teaching Award
1984	Outstanding Faculty Teacher Award, UCSF
1983	Sandoz Award for Outstanding Neurology Resident, UCSF
1983	Scholarship Recipient, Cold Spring Harbor Neurobiology Seminars
1977	Trent Prize in the History of Medicine, Duke
1977	Brody Scholar in the History of Neurosciences, Duke

1975-77 Mary Duke Biddle Scholar, Duke

1974 Graduation with Honor, Caltech

1974 McKinney Prize for Humanities, Caltech

1970-74 Alfred P. Sloan Scholar, Caltech

1970, 73-74 Athletic Letters, Caltech (Football, Track)

RESEARCH GRANTS AND FELLOWSHIPS RECEIVED:

Name	% Effort	Period Covered	$ Amount
Active:			
Evanthea Foundation Proof of concept trial PI: Bredesen	5	10/01/17-06/30/19	1,250,000
Robinson Charitable Trust Alzheimer's research PI: Bredesen	5	01/01/15-12/31/18	160,000
Gehl Foundation ApoE transcriptional effects PI: Bredesen	5	07/01/16-06/30/18	125,000
Four Winds Foundation ApoE in Alzheimer's PI: Bredesen	5	07/01/16-06/30/17	250,000
Completed:			
Sponsored Research Holdings, LLC Bredesen Accelerate Project PI: Bredesen	5	05/10/13 -12/31/14	1,499,037 Total
Joseph Drown Fdn Alz. Drug Discovery Network PI: Bredesen	0	01/01/14- 12/01/14	100,000 Yr. 1
Alzheimer's Association Part the Cloud Translational Res for Alz. Disease PI: Bredesen	10	10/01/13-09/30/14	200,000 Total

NIH – Nat'l Inst. on Aging R21 AG036975 APP Signaling Network PI: Bredesen	5	9/30/12- 8/31/14	520,163 Total
NIH- Nat'l Inst. on Aging R21 AG041456 Screening for APPNeo Inhibitors PI: John Co-PI: Bredesen	2	08/01/12-07/31/14	323,443 Total
NIH – Nat'l Inst. on Aging Eureka R01 AG034427 Novel prionic mechanism underlying Alzheimer's Dis. PI: Bredesen	40	07/15/09-06/30/13	1,510,554 Total
Bechtel Clinical Trial Development of the First Therapeutic System for Alz. Dis. PI: Bredesen	33	09/16/11-09/15/13	2,000,000 Total
Rosenberg Venture Philanthropy Challenge Grant – Alzheimer's Dis. Research PI: Bredesen	31	04/22/10- 04/21/13	2,850,000 Total
Hoag Family Fund 9/12 ADDN Network PI: Bredesen	10	04/01/12-09/01/12	500,000 Total
NIH/NCRR U54 RR024346 Interdisciplinary Research Consortium in Geroscience (U54) UL1 RR024917: 1 of 11 (Bredesen RL1 ES016655 (Lithgow; 3 of 11) PI: Bredesen	4	09/20/07-06/30/12	$25,000,000 Total
BioMarin Pharmaceutical, Inc. Netrin Project, Buck/BioMarin License and Collaboration Agreement PI: Bredesen	10	07/20/10-05/20/12	840,000 Total
Joseph Drown Fdn Alzheimer's Dis Therapy Development Network PI: Bredesen	5	07/01/07-06/30/11	100,000 Yr. 1
ISOA Grant 280602 ID of inhibitors for C-terminal D664 cleavage of APP Co-PI: Bredesen	5	03/01/10-02/28/11	115,000 Total

Rosenberg Foundation Fellowship Support Alzheimer's Disease Translational Research PI: Bredesen	36	12/01/08-06/30/10	325,351 Total
Rosenberg Foundation Alzheimer's Disease Research Prog PI: Bredesen		10/01/09-06/30/10	400,000 Total
W.M. Keck Foundation Why Aging Causes Disease Co-PI-Bredesen	5	07/01/08-06/30/10	750,000 Total
NIH Nathan Shock Center P30 AG025708 (Bredesen) Basic Mechanisms in Aging and Age Related Disease Administrative/Program Enrichment PI: Bredesen	6	07/01/05/06/30/10	3,851,657 Entire Bredesen core A 314,299 Total
NIH-AD Research Ctr., UCSD 2P50-AG05131 (Thal) AD Research Centers Co-PI: Bredesen	5%; no salary	05/01/04-03/31/09	52,876 Each year
NIH NCRR C06 RR020660 (Bredesen) Extramural Research Facilities Construction Projects Center for Integrative Studies of Aging Extramural Research Facilities Construction Projects award to support a Center for Integrative Studies of Aging at the Buck Institute for Age Research. PI: Bredesen	0	09/30/04-06/30-09	2,900,000 Total
Alzheimer's Association A role for the intracytoplasmic cleavage of APP in Alzheimer's disease PI: Bredesen	1	08/01/06-07/31-09	239,978 Each year
RS1-00163-1 California Institute for Regenerative Medicine (CIRM)Programmed cell death pathways in embryonic stem cells PI: Bredesen	5	08/01/07-10/31/09	748,298 Each year
California Institute for Regenerative Medicine (CIRM) SEED RS1-00163-1	5	08/01/07-10/31/09	748,298 Total

Programmed cell death pathways in embryonic stem cells PI: Bredesen			
Neurobiological Technologies, Inc. (NTI) Dev't of recombinant Netrin-1 and Netrin-1 mimetics for AD PI: Bredesen	N/A	03/01/08-02/28/09	1,200,000 Total
NIH/NCRR G20 RR02277 Developing and improving institutional animal resources PI: Bredesen	1	06/01/07-05/31/09	675,119 Total
Alz. Assn, IIRG-06-27717 A role for the intracytoplasmic cleavage of APP in Alz. Disease PI: Bredesen	1	08/01/06-07/31/09	719,934 Total
NIH/NINDS, R01 NS045093 Mechanism of apoptosis induction by the receptor DCC PI: Bredesen	9	02/01/03-01/31/08	1,699,455 Total
NIH R01 AG012282 Mechanism of inhibition of Neurodeg and aging PI: Bredesen	3%; no salary	05/01/94-03/31/08	1,850,007 Total
NIH/NIA T32 AG020495 Training in Age-Related Disease and Aging Res PI: Bredesen	N/A	05/01/02-04/30/08	799,502 Total
NIH-NINDS R01 NS033376 Competing Continuation Novel Apoptotic pathways activated by misfolded proteins PI: Bredesen	9	07/01/03-06/30/08	2,269,048 Total
NIH T32 AG00278 (Kenyon) Aging and neurodegenerative diseases Co-PI: Bredesen	N/A	06/01/02-04/30/07	320,986 Total
ISOA Grant Screening for Alzheimer's therapeutics PI: Bredesen	5	12/01/06-12/23/07	50,000 Total

NIH Conference Support R13-AG026961 Buck Institute Symposia on Aging: Pharmacology of Lifespan Extension PI: Bredesen	N/A	06/01/05-05/31/06	20,000 Total
American Biosciences Inc. Novel and hunter killer peptides PI: Bredesen	5	06/15/01-06/14/05	2,428,000 Total
Drown Foundation Novel Therapeutics for Alz. Disease PI: Bredesen	5	12/01/01-11/30/05	100,000 Each year
Ellison Medical Foundation 2005 Buck Institute Symposium on Aging PI: Bredesen	N/A	10/06/05-10/08/05	10,000 Total
Glenn Foundation 2005 Buck Institute Symposium on Aging PI: Bredesen	N/A	10/06/05-10/08/05	10,000 Total
NIH-NCI P01 CA 69381 Program Project Grant (Reed) Signal transduction and cell death regulation The research aims of this component of the proposal are designed to address the molecular mechanisms of apoptosis mediated by DCC. Componen3-Bredesen	2; no salary	07/01/00-04/30/04	132,160 Total
ISOA Grant 220901 Development of Drugs for a new Therapeutic Target PI: Bredesen	5	09/01/02-08/31/03	100,000 Total
NIH - NINDS R01 NS35155 Familial ALS: Mechanism of Initiation PI: Bredesen	10	10/01/99-03/31/02	109,083 Total
DAMD17-98-8581 USAMRMC Novel Synthetic Hunter-Killer Peptides Target and Destroy Prostate Cancer PI: Bredesen	5	05/15/00-01/14/02	290,014 Total

DAMD17-98-1-8613 USAMRMC The Mechanism by which α-Synuclein Mutant Induces Cell Death PI: Bredesen	10	07/01/98-10/31/02	529,242 Total
Muscular Dystrophy Assn. Familial ALS: Mechanism of Initiation PI: Bredesen	1	01/01/97-12/31/99	25,263 (Total) DC only

LECTURES AND PRESENTATIONS (ABRIDGED FROM OVER 300)

1. What can AIDS teach us about neurologic illness? Letterman Army Hospital, 1984.
2. What can AIDS teach us about neurologic illness? Stanford University Department of Neurology, 1985.
3. Neurologic complications of AIDS. Stanford University Department of Neurosurgery, 1985.
4. Neurologic complications of AIDS. University of Chicago Symposium on Neuroimmunology, 1985, 1986, 1987, 1989.
5. Neurologic complications of AIDS. University of North Carolina, 1986.
6. Neurologic complications of AIDS. Kaiser Hospital, Oakland, 1986.
7. Secondary viral infections of the nervous system in AIDS. UCSF Symposium on AIDS and the Nervous System, 1986.
8. What can AIDS teach us about neurologic illness? Santa Clara Valley Medical Center, Department of Neurology, 1987.
9. Peripheral nervous system complications of AIDS. San Francisco Neurological Society, 1987.
10. Update on AIDS. UCSF Department of Neurology Update Course, 1987.
11. Dementia in a test tube: promises and pitfalls. University of Kentucky, 1987.
12. Neurologic complications of AIDS. Child Neurology Symposium on AIDS, San Diego, 1987.
13. Neurologic complications of AIDS. Federal Correctional Institute, Lexington, Kentucky, 1988.
14. Mechanisms of AIDS-related neurologic disease. AAN (dinner seminar), 1988.
15. What can AIDS teach us about neurologic illness? University of Utah, 1989.
16. AIDS and the nervous system. Kaiser Hospitals (closed circuit), 1989.
17. *Sic transit gloria mundi*: reversible immortalization of neural cells. University of Utah, 1989.
18. Genetic engineering of neural transplants. Sepulveda VAH, 1989.
19. Use of temperature-sensitive immortalized neural cells in neurobiology. UCLA Molecular Neurobiology Program, 1989.
20. Alzheimer's disease: can we model neurodegenerative disease in vitro? Neurology Grand Rounds, UCLA, 1989.
21. The neurology of human retroviral infections. UCSF Neurology Update Course (guest faculty member), 1990.
22. Strategies for gene transfer in human disease. Interdepartmental Conference, UCLA (moderator and speaker), 1990.

23. Gene therapy strategies for neurological disease. International Ataxia Meeting, Boston, 1991.
24. Reiterative antisense cloning. Applied Biosystems, Inc., Foster City, 1991.
25. A cell culture model of Alzheimer's disease. Athena Neuroscience, South San Francisco, 1991.
26. Dead neurons society—neural degeneration and replacement. University of Kansas Department of Physiology, Kansas City, 1991.
27. Neural degeneration and engineered replacement. University of Rochester Department of Neurology, Rochester, 1992.
28. Gene therapy for neurological disease: a look at the future. American Academy of Neurology breakfast seminar, San Diego, 1992.
29. Necrogenes and death suppressor genes. University of Rochester Department of Biochemistry, Rochester, 1992.
30. Gene therapy for neurological disease: a look at the future. American Academy of Neurology 1/2 day course, New York, 1993.
31. Genes that inhibit neural cell death. American Academy of Neurology (Neurochemistry course), New York, 1993.
32. Genetic modulation of neural cell death. Athena Neuroscience, South San Francisco, 1993.
33. Genetic modulation of neural cell death. Stanford University Dept. of Neuroscience, Stanford, 1993.
34. Modulation of neural apoptosis and necrosis. International Conference on Apoptosis in AIDS and Cancer (organizers: L. Montagnier and L. D. Tomei). Paris, 1993.
35. Genetic modulation of neural cell death. Mechanisms of Physiological Cell Death (organizer: F. Wong). Duke University, Durham, 1993.
36. The low-affinity NGF receptor and basal forebrain neurodegeneration. French Foundation for Alzheimer Research, 1993.
37. Neural apoptosis: genetic and biochemical modulation. Merck Pharmaceuticals, Rahway, New Jersey and West Point, Pennsylvania, 1993.
38. Genetic control of neural cell death. Umeå Center for Molecular Pathogenesis, Umeå, Sweden, 1993.
39. Genetic modulation of neural apoptosis. Third Altschul Symposium, University of Saskatchewan, Canada, 1994.
40. Genetic modulation of neural apoptosis. Cambridge Healthtech Institute Symposium on Apoptosis, 1994.
41. Genetic modulation of neural cell death. Association for Research in Vision and Ophthalmology (ARVO) Special Minisymposium on Mechanisms of Cell Death, 1994.
42. Control of neural apoptosis. FASEB Neuroimmunology Symposium, 1994.

43. Genetic control of neural cell death. University of Massachusetts Dept. of Molecular Medicine, 1994.
44. Genetic control of neural cell death. Stanford University Dept. of Genetics, 1994.
45. Genetic modulation of neural apoptosis. XIX Princeton Conference on Stroke, Boston, 1994.
46. Genetic control of neural cell death. Harvard Neuroscience Seminar Series, Massachusetts General Hospital, 1994.
47. Genetic control of neural cell death. Cold Spring Harbor Course (L. Reichardt, T. Schwarz, R. McKay, organizers), 1994.
48. Is apoptosis mediated by reactive oxygen species? Gordon Winter Conference on Free Radicals, Ventura, California, 1994.
49. Bcl-2 and the role of superoxide anion in neural cell death. Society for Neuroscience Satellite Symposium, Molecular Mechanisms of Disease, Miami, 1994.
50. Genetic control of neural apoptosis. Society for Neuroscience Satellite Symposium, Neural Apoptosis, Miami, 1994.
51. Genetic control of neural apoptosis. Andrus Gerontology Center, University of Southern California, 1994.
52. Neural apoptosis and the concept of subcellular cell death. UCLA Center on Aging, 1994.
53. Genetic control of neural cell death. John Hopkins University, Department of Neurology, 1995.
54. Control of neural apoptosis. Keystone Symposium on Apoptosis, 1995.
55. Genetic control of neural cell death. Keystone Symposium on Neurodegenerative Disease, 1995.
56. Control of neural death. Cold Spring Harbor course on Neurodegenerative Disease Mechanisms (D. Choi, W. Mobley), 1995.
57. Implications of apoptosis research for the study of neurodegenerative diseases. Child Neurology Society Lectureship, University of Rochester, 1996.
58. Principles emerging from the study of developmental neural cell death. Child Neurology Society Lectureship, University of Rochester, 1996.
59. Thanatopsis: principles emerging from the study of neural cell death. Cold Spring Harbor course on Neurodegenerative Disease (W. Mobley, S. Gandy, S. Prusiner), 1996.
60. Receptors and effectors in the neural cell death program. Juan March Foundation Workshop on Programmed Cell Death in the Nervous System (R. Oppenheim, E. Johnson), Madrid, 1996.
61. The initiation of amyotrophic lateral sclerosis. Lou and Eleanor Gehrig Lectureship, Columbia University, 1996.
62. Thanatopsis: principles emerging from the study of neural cell death. Montreal Neurological Institute, 1996.

63. Amyotrophic Lateral Sclerosis: Promotion of apoptosis by mutant SOD1 proteins? Annual Meeting of the American Society of Human Genetics, 1996.

64. Mutant SOD and cell death. 7th International Symposium on ALS/MND, Chicago, 1996.

65. Thanatopsis: principles emerging from the study of developmental neuronal death. 24th Meeting of the International Society for Oncodevelopmental Biology and Medicine (ISOBM), 1996.

66. 'Fat chance' and other molecules controlling neural cell death. UCSD, Cellular and Molecular Medicine seminar, 1996.

67. CuZnSOD as a peroxidase. SEP/ALS Symposium, Kansas City, 1997 (organizers H. R. Horvitz and R. Brown).

68. Neural apoptosis. Immune Regulatory Pathways in Autoimmune and Neuroimmunologic Diseases Symposium, Tucson, 1997 (organizers M. Ballow and M. Dalakas).

69. Neural apoptosis in development and degenerative disease. Verbier Symposium, Verbier, Switzerland, 1997 (organizers A. Kato and P. Aebischer).

70. Thanatopsis: control of neuronal apoptosis. Keystone Symposium on Alzheimer's Disease, Tamarron, Colorado, 1997 (organizers B. Yankner and A. Roses).

71. Neuronal cell death in ALS. Molecular Biology of Aging Symposium, American Society for Biochemistry and Molecular Biology Annual Meeting, San Francisco, 1997 (organizers J. Campisi and H. Warner).

72. Apoptosis and neurodegenerative disease. Neuron Loss and Neuron Atrophy During Aging: The Frontier Between Health and Disease. XVI World Congress of Neurology, 1997.

73. Thanatopsis: control of neuronal cell death. Messengers of Life and Death: Protective and Toxic Neuron Signaling Pathways. University of Kentucky, 1997 (organizer M. Mattson).

74. Control of neuronal apoptosis. Duke University Cellular and Molecular Biology seminar series, 1997.

75. Neural apoptosis. Cold Spring Harbor course on neurodegenerative disease (S. Gandy, S. Sisodia), 1997.

76. The relationship between developmental and degenerative neural cell death. Harvey Conference: Novel mechanisms of neurodegeneration. London, 1998.

77. The emerging relationship between developmental and degenerative neural cell death. Keystone Symposium on Alzheimer's Disease, 1999.

78. Control of cell death in age-associated diseases. Keystone Symposium on Aging, 1999.

79. Paraptosis, new cell death program with new targets for drug discovery. MitoKor, San Diego, California, 1999.

80. Classical and non-classical cell death programs in neurological disease. Advances in Neurobiology, NIDDK, NIH, Bethesda, Maryland, 1999.

81. How can new advances lead to new therapies for Alzheimer's Disease and other neurodegenerative diseases? UCLA Brain Research Institute, 1999.

82. Dependence receptors: the molecular basis of cellular addiction. Gordon Conference on Apoptosis, 1999.

83. Glutamine repeat proteins and formation of toxic aggregates in neurodegeneration. Winter Conference on Brain Research, Breckenridge, Colorado, 2000.

84. Apoptosis in neurologic disease. Recent Advances in Neurology, University of California San Francisco, 2000.

85. Apoptosis. 22nd Princeton Conference on Cerebrovascular Disease, Redwood City, CA.

86. Role of cell death programs in neurologic disease. Neurology Grand Rounds, California Pacific Medical Center, San Francisco, California, 2000.

87. Cellular addiction receptor and their relationship to Alzheimer's Disease. Mechanisms of Neurodegeneration, World Alzheimer Congress, Chicago, Illinois, 2000.

88. Neurological Breakthroughs Panel Meeting, Rand Corporation, Santa Monica, California, 2000.

89. Why do neurons die as we age and what can we do about it? Intensive Course in Geriatric Medicine and Board Review, University of California Los Angeles School of Medicine, Santa Monica, California, 2000.

90. An alternative, non-apoptotic cell death program. Keystone Symposium on Molecular Mechanisms of Apoptosis, 2001.

91. An alternative, non-apoptotic form of programmed cell death. Keystone Symposium on Molecular Basis of Neurodegenerative Disease, 2001.

92. A novel form of cell death and its relation to neurodegenerative disease. Riken Brain Science Institute, Japan, 2001.

93. A novel program for cell death, and its relationship to disease states. H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, 2001.

94. Thanatopsis: Viewing Cell Death as a Means to Develop Novel Therapeutics. Dean's Lecture Series, University of Kentucky, November 27, 2001.

95. Cell death programs: alternatives to apoptosis. North Carolina Society of Toxicology 2002 Annual Meeting, National Institute of Environmental Health Sciences, Research Triangle Park, NC, March 2, 2002.

96. Aging nervously: issues central to aging and the nervous system. Nathan Shock Workshop on the Aging in the Nervous System, University of Michigan, May 13-14, 2002.

97. A non-apoptotic form of programmed cell death and its role in neurodegeneration. Centre de Genetique Moleculaire et Cellulaire, Universite Claude Bernard, Lyon, France, July 5, 2002.

98. Which way did they go? Alternative cell death pathways and their roles in disease. University of Colorado, Oct. 28, 2002.

99. Which way did they go? Alternative cell death programs and their roles in disease. Australian Health and Medical Research Congress (AHMRC), November 26-29, 2002.

100. Thanatopses: View of apoptosis and alternative cell death programs. 2003 Miami Nature Biotechnology Winter Symposium, February 1-5, 2003.

101. Neuronal cell death: apoptosis vs. necrosis. American Society for Experimental Neuro Therapeutics (ASENT), Washington, D.C. March 14, 2003.

102. II b or not IIb? The many programs of cell death. National Cancer Institute, Fort Detrick, Maryland, April 23, 2003.

103. The concept of Dependence Receptors: Seeing how the other half die. Foundation des Treilles, Tourtour, France. July 2-7, 2003.

104. Molecular mechanisms of neuronal cell death in aging related neurodegenerative diseases. Asia-Pacific Conference and Exhibition on Anti-Ageing Medicine 2003. Raffles City Convention Center, Singapore. Sept. 8-11, 2003.

105. Mitochondrial role in cell death programs - old & new. Oxygen Club of California (OCC/LPP) Santa Barbara, California, March 11, 2004.

106. A beautiful mind, wasted: novel neural cell death pathways. St Jude's Hospital Memphis, TN, January 15, 2004.

107. A beautiful mind, wasted: new forms of cell suicide and their roles in disease. Encino-Tarzana Medical Center, Tarzana, CA March 30, 2004

108. Coupling endoplasmic reticulum stress to the cell death program. American Society for Microbiology, 104th General Meeting, New Orleans, LA May 25, 2004.

109. Toward a mechanistic taxonomy of cell death programs. ISOA Meeting, New York, New York June 4, 2004.

110. The role of the APP intracytoplasmic domain in Alzheimer's disease. 9th International Conference on Alzheimer's Disease and Related Disorders, the Alzheimer's Association/Alzheimer Research Consortium, Pennsylvania, PA July 17, 2004.

111. A beautiful mind, wasted: novel neural cell death pathways and their roles in disease states. Grand Rounds Lecture to Neurology and Neuroscience New York Presbyterian Hospital-Cornell Medical Center, New York NY July 21, 2004.

112. Is there a fountain of youth for the brain? Wonderfest 2004. The Bay Area Festival of Science, Stanford and Berkeley, November 7, 2004.

113. Apoptosis—an update. 38th Annual Recent Advances in Neurology, UCSF, San Francisco CA, February 16-18, 2005.

114. Apoptosis vs. alternative cell death programs. 96th American Association for Cancer Research Annual Meeting, Anaheim, CA. April 16-20, 2005

115. A beautiful mind, wasted: novel pathways to neural cell death. The Sid Gilman and Carol Barbour Lectureship in Experimental Neurology, University of Michigan, Ann Arbor MI, May 4, 2005.

116. An APP-mediated cell death pathway. Bay Area Alzheimer's Disease Research Symposium, the Alzheimer's Association and the Gladstone Institute of Neurological Disease, San Francisco CA, May 26, 2005.

107. Regeneration or degeneration? The Cellular decision-making process Kentucky Spinal Cord and Head Injury Research Trust Symposium, Louisville, KY, June 8-11, 2005.

108. Toward a Mechanistic Taxonomy of All Cell Death Programs Loma Linda University, Loma Linda, CA October 28, 2005.

109. Keynote Speech at Dominican University Ground breaking ceremony, Nov. 3, 2005.

110. Alzheimer's disease: new view, new ligand, new therapeutic approach, Biopolis, Singapore, March 28, 2006.

111. The Emerging Field of Academic Drug Development, Biopolis, Singapore, March 28, 2006.

112. Alzheimer's Disease: New View, New Ligand, New Therapeutic Approach, LBNL Life Sciences Division Seminar, UC Berkeley, California, May 2, 2006.

113. Developing the Cures of the Future: Tennessee is not the only Volunteer State, Keynote Speaker at Benedetti Leadership Luncheon, Petaluma, California, May 5, 2006.

114. A Beautiful Mind, Wasted: Alzheimer's Disease in 2006 and Beyond, 8th Annual Updates on Dementia Conference, Alzheimer's Assn of Northern California, Stanford University, May 15, 2006.

115. Keynote Lecture: Mechanisms of Cell Death – Princeton Conference on Cerebrovascular Disease, Portland, Oregon, May 19, 2006.

116. A role for the cleavage of APP at Asp664 in the development of AD-like deficits in a mouse model, Alzheimer's Association Medical Scientific Advisory Council Research Symposium, UC Davis, California June 30, 2006.

117. Dependence receptors: emerging concepts and unanswered questions, 2nd Int'l Dependence Receptors Meeting, Buck Institute, Novato, CA Sept. 14-16, 2006.

118. Apoptosis vs. Alternative Cell Death Programs", Molecular Genetics of Aging Conference, Cold Spring Harbor Laboratory, New York, October 4-8, 2006.

119. APP-Based Neuroprotective Strategies, 7th International Conference on Alzheimer's Disease Drug Discovery, Westin Hotel, NY, October 12-13, 2006.

120. APP intracytoplasmic domain processing mediates the Alzheimer's phenotype in transgenic mice", 2006 Society for Neuroscience Annual Meeting's Press Conference, , Georgia World Congress Center, Atlanta, Georgia, October 15, 2006.

121. The Functional Roles of the Amyloid Precursor Protein Cytoplasmic Domain, 2006 Society for Neuroscience Minisymposium, Georgia World Congress Center, October 17, 2006.

122. Apoptosis and Aging, Buck Stanford Aging Symposium, Munzer Auditorium, Stanford University, California, November 6, 2006.

123. A Beautiful Mind, Wasted: Novel Neural Cell Death Pathways, University of Massachusetts Medical School, Worcester, MA, November 16, 2006.

124. Toxicity or Transduction? Neurodegenerative Disease Mechanisms, University of California San Diego Neuroscience Graduate Lecture, La Jolla, CA, January 16, 2007.

125. A Beautiful Mind, Wasted: Novel Cell Death Pathways, University of California, Riverside Neuroscience Seminar Series, Riverside, CA, January 29, 2007.

126. Memory and Forgettory: New Targets for Treating Alzheimer's Disease – North Bay Alzheimer's Assoc., Petaluma. CA, March 22, 2007.

127. Keynote Lecture – 21st National Conference on Undergraduate Research – Dominican University, San Rafael, CA, April 13, 2007

128. Toward a Mechanistic Taxonomy of Cell Death – Apoptotic and Non-Apoptotic Cell Death Pathways - Keystone Symposium – Portola Plaza Hotel, Monterey, CA, April 15-20, 2007

129. A Beautiful Mind Wasted – How Can We Save It? Novel Insights Into Alzheimer's Disease – California Academy of Medicine, Concordia Argonaut Club San Francisco, CA, April 28, 2007

130. Alzheimer's disease meets new technology head on – Institute for Bioengineering and Nanotechnology, Biopolis, Singapore – May 14, 2007

131. A Brain Signaling its Own Degeneration - Molecules to Medicine Symposium– UC San Francisco Genentech Hall , September 6, 2007

132. Three lectures at the 1st Dependence Receptors and 10th Neuroblastoma Joint Meeting – Japanese Cancer Association, Yokohama, Japan – October 1-7, 2007.

133. Hyper-memory, Forgettory, and Alzheimer's Disease Mechanisms -- Stanford University Alzheimer's Series Lecture, Menlo Park, CA – October 17, 2007.

134. Talk on Building/Institute, Endowed Chair & Network Grantees -- Larry L. Hillblom Foundation -- 6th Annual Scientific Meeting -- Frances C. Arrillaga Alumni Center – Stanford University November 13-14, 2007.

135. Disease: How It Works And How To Prevent It -- Stanford Club of Marin -- Held at Northern Trust Bank, Mill Valley, CA, November 28, 2007.

136. Cell Death, Signaling, and Alzheimer's Disease – Toxicity or Transduction? -- Mayo Clinic Lecture -- Jacksonville, FL, December 7, 2007.

137. Cell death programs, and brain diseases -- Scientific Symposium: Honoring Contributions to the Field of Cell Death/Programmed Cell Death --Caspary Auditorium, Rockefeller University, December 10-11, 2007

138. Hyper-memory, Forgettory, and Alzheimer's Disease Mechanisms -- UC San Diego Neuroscience Grand Rounds lecture -- Skaggs School of Pharmacy, January 11, 2008

139. Neuronal Death as a Therapeutic Target -- 41st Recent Advances in Neurology – San Francisco, CA, Feb. 14, 2008.

140. Dependence Receptors: Concept and Role in Neural Survival -- Advances in Neuroblastoma Research 2008 -- Chiba, Japan, May 21-24, 2008

141. The Emerging Signaling Network Underlying Alzheimer's Disease -- Alzheimer's Research Symposium -- Gladstone Institutes, San Francisco, CA, June 23, 2008.

142. How to Stiff Arm Aging - Talk #1; Geroscience: A New Science About Much More than Growing Old - Talk #2 – Bohemian Club, Monte Rio, CA – July 18 and 19, 2008

143. Why Congress Can't Stop Aging, But Can Have a Monumental Impact on its National Effects -- Congressional Biomedical Caucus, Capitol Hill Washington, DC – July 22-23, 2008

144. The Four Horsemen vs. The "Wholly" Trinity: A New Look at Alzheimer's Disease -- Talk #1; Research and Healthy Aging -- Talk #2 -- University of Groningen, The Netherlands, August 25-26, 2008

145. The Four Horsemen vs. The "Wholly" Trinity: A New Look at Alzheimer's Disease—National Institutes of Health, National Advisory Council on Aging (NACA), September 25, 2008

146. The Four Horsemen or "Wholly" Trinity: A New Look at Alzheimer's Disease—University of Kentucky, Sanders Brown Center on Aging, September 26, 2008

147. Keynote Presentation: Current Perspectives on Research and Treatment -- 4th annual Alzheimer's Disease: Circle of Care – Foster City, CA, November 22, 2008

148. Molecular Switches and Alzheimer's Disease: A New View -- Special Biocentrum Helsinki seminar, Helsinki, Finland, February 12, 2009

149. Prionics, Molecular Switches, and Alzheimer's Disease – President's Lecture Series – Burnham Institute, La Jolla, CA, June 23, 2009

150. Public lecture: *New Insights into Alzheimer's Disease and a Potential Prevention* Scientific lecture: *Prionics, Molecular Switches, and New Insights into Alzheimer's Disease* -- 2009 Landa Lecture -- University of Utah – Salt Lake City, UT, September 8 and 9, 2009

151. Plenary Session 2: What Can We Learn about HD from Other Diseases, *Prionics, Molecular Switches, and Neurodegenerative Signaling in AD* -- 2009 World Congress on Huntington's Disease, Vancouver, BC, September 13-15, 2009

152. "Prionics, Molecular Switches, and Alzheimer's Disease"-- ADRC Tuesday Seminar, University of Washington, St. Louis – St. Louis, MO, March 2, 2010

153. Non-Conventional Cell Death Pathways: Role of Cell Death Signaling in Alzheimer's Disease -- Keystone Symposia -- Cell Death Pathways: Apoptosis, Autophagy and Necrosis -- , Vancouver, British Columbia, March 16, 2010

154. Keynote Lecture: Keeping Your Memory: New Insight and New Therapeutic Approach to Alzheimer's Disease -- Northern California & Northern Nevada Alzheimer's Association, Alzheimer's Education Conference – Rohnert Park, CA, April 26, 2010

155. The Latest Trends in Alzheimer's Research -- LTCIF 2010 Forum -- Tampa, FL, May 5 – 7, 2010

156. The Emerging Relationship Between Neural Development and Degeneration –

Alzheimer's Researchers' Symposium Program – Cal Alumni House, Berkeley, CA, June 28, 2010

157. *Alzheimer's Disease: A Remarkable New Form of Cancer* –Emory University, Atlanta, GA, October 12, 2010

158. How to Understand and Prevent Alzheimer's Disease – Midway Fdn for Integrative Medicine—Midway College, Midway, KY, October 23, 2010

159. Molecular Switches, Prionics and Alzheimer's Disease – UT Health Science Center, San Antonio, TX, October 25, 2010

160. Forgetting Multiplies: New Insight into Alzheimer's Disease Mechanistics – California German American Business Association, San Francisco, CA, March 10, 2011

161. Forgetting Multiplies: the Basis of Alzheimer's Disease – Bay Area Neuroscience Gathering, Touro University, Vallejo, CA, April 28, 2011

162. Novel approaches to therapeutic development for Alzheimer's disease—Alzheimer's Researchers' Symposium—Stanford University, Stanford, CA, June 28, 2011

163. Alzheimer's Disease: A Remarkable Form of Cancer – University of Lyon, France, July 13, 2011

164. Systems Therapeutics: New Opportunities for Alzheimer's RX – EMS, Sao Paolo, Brazil August 17, 2011

165. Brain Wars Episode IV - Singularity University NASA Ames Research Center Moffett Field, CA, October 8, 2011

166. Alzheimer's Disease Pathogenesis: Does the Dogma Make Sense? – SF Neurological Society, SF, October 14, 2011

167. Futuremed – Singularity University NASA Ames Mountain View, CA, February 2, 2012

168. Memory Home Care Solutions 2012 Annual Meeting Keynote Lecture, St. Louis, MO May 5, 2012

169. Role of Cell Death Signaling in Alzheimer's Disease - Keystone Symposium Aging and Disease, Tokyo, Japan, October 22-25, 2012

170. Prionic loops, anti-prions, and dependence receptors mediating neurodegeneration – Science Fall Celebration Event in honor of S. Prusiner, Nobel Laureate, Pollenzo, Bra Italy, Nov. 4-5, 2012

171. Systems Therapeutics for Alzheimer's Disease and MCI - 3rd Annual Gladstone/DZNE Workshop - From Science to Therapeutics: The Best Way Forward - April 15-17, 2013

172. Systems Therapeutics--New Approach to Alzheimer's Disease Treatment – SF Veterans Affairs Medical Center, San Francisco, CA June 7, 2013

173. Novel classes of therapeutics for AD & MCI -Alzheimer's Researchers Symposium, UC Berkeley, CA, June 10, 2013

174. Systems therapeutics, President Obama, and the end of Alzheimer's disease" - Turken Lecture – Neurology Grand Rounds at UCLA December 4, 2013

175. Next Generation Therapeutics for Neurodegenerative Diseases – Neurology Science Day UCLA – March 5, 2014

DALE ERIC BREDESEN
CURRICULUM VITAE

PUBLICATIONS (CHRONOLOGICAL ORDER)/BIBLIOGRAPHY:

A. ARTICLES (PEER REVIEWED)

1. Wrighton M, **Bredesen DE**, Hammond GS and Gray HB. Deactivation of biacetyl triplets by cyanocobaltate (III) complexes. *J Am Chem Soc, Chem Comm* 1972;**18**:1018-1019.
2. Wrighton M and **Bredesen DE**. Symmetrical cleavage of the metal-metal bond in decacarbonyldirhenium (O) by ultraviolet irradiation. *J Organmet Chem* 1973;**50**:C35-C38.
3. Wrighton M and **Bredesen DE**. Photochemistry of aquo- and hydroxopenta-cyanocobaltate (III). *Inorg Chem* 1973;**12**:1707-1709.
4. **Bredesen DE**, McCarty KS, Jr, Schomberg D, Kramer R and Hammond C. Ultrastructural effects of 2-bromoergocryptine on prolactin-producing human pituitary adenomas. *Proc Elec Micro Soc Amer* 1977;536-537.
5. McCarty KS, **Bredesen DE** and Vogel FS. Neoplasms of the anterior pituitary. *Neurosurgery* 1978;**3**:96-104.
6. Cutler JR, **Bredesen DE**, Edwards R and Simon RP. Failure of naloxone to reverse vascular neurologic deficits. *Neurology* 1983;**33**:1517-1518.
7. Raskin NH, **Bredesen DE**, Ehrenfeld WK and Kerlan RK. Periodic confusion caused by congenital extrahepatic portacaval shunt. *Neurology* 1984;**34**:666-669.
8. Dix RD, **Bredesen DE**, Erlich KS and Mills J. Recovery of herpes viruses from cerebrospinal fluid of immunodeficient homosexual men. *Ann Neurol* 1985;**18**:611-614.
9. Levy RM, **Bredesen DE** and Rosenblum ML. Neurological manifestations of the acquired immunodeficiency syndrome (AIDS): experience at UCSF and review of the literature. *J Neurosurg* 1985;**62**:475-495.
10. Parry GJ and **Bredesen DE**. Sensory neuropathy with low-dose pyridoxine. *Neurology* 1985;**35**:1466-1468.
11. **Bredesen DE**, Levy RM and Rosenblum ML. The neurology of human immunodeficiency virus infection. *Q J Med* 1988;**68**:665-677.
12. Levy RM and **Bredesen DE**. Central nervous system dysfunction in acquired immunodeficiency syndrome. *J Acquir Immune Defic Syndr* 1988;**1**:41-64.
13. Levy RM, **Bredesen DE** and Rosenblum ML. Opportunistic central nervous system pathology in patients with AIDS. *Ann Neurol* 1988;**23**:S7-12.
14. Rosenblum ML, Levy RM and **Bredesen DE**. Neurosurgical implications of the acquired immunodeficiency syndrome (AIDS). *Clin Neurosurg* 1988;**34**:419-445.
15. Rosenblum ML, Levy RM, **Bredesen DE**, So YT, Wara W and Ziegler JL. Primary central nervous system lymphomas in patients with AIDS. *Ann Neurol* 1988;**23**:S13-16.
16. Scott MR, Butler DA, **Bredesen DE**, Walchli M, Hsiao KK and Prusiner SB. Prion protein gene expression in cultured cells. *Protein Eng* 1988;**2**:69-76.
17. Engstrom JW, Lowenstein DH and **Bredesen DE**. Cerebral infarctions and transient neurologic deficits associated with acquired immunodeficiency syndrome [see comments]. *Am J Med* 1989;**86**:528-532.

18. Ho DD, **Bredesen DE**, Vinters HV and Daar ES. The acquired immunodeficiency syndrome (AIDS) dementia complex [clinical conference]. *Ann Intern Med* 1989;**111**:400-410.
19. **Bredesen DE**, Hisanaga K and Sharp FR. Neural transplantation using temperature-sensitive immortalized neural cells: a preliminary report. *Ann Neurol* 1990;**27**:205-207.
20. Kahn JO, Kaplan LD, Gambertoglio JG, **Bredesen DE,** Arri CJ, Turin L, Kibort T, Williams RL, Lifson JD and Volberding PA. The safety and pharmacokinetics of GLQ223 in subjects with AIDS and AIDS-related complex: a phase I study [see comments]. *Aids* 1990;**4**:1197-1204.
21. Levy RM, **Bredesen DE** and Rosenblum ML. Neurologic complications of HIV infection. *Am Fam Physician* 1990;**41**:517-536.
22. Levy RM, Mills CM, Posin JP, Moore SG, Rosenblum ML and **Bredesen DE**. The efficacy and clinical impact of brain imaging in neurologically symptomatic AIDS patients: a prospective CT/MRI study. *J Acquir Immune Defic Syndr* 1990;**3**:461-471.
23. Singer EJ, **Bredesen DE** and Baringer JR. Cognitive dysfunction in an HIV-infected patient. *Hosp Pract (Off Ed)* 1992;**27**:91-99, discussion 99-100.
24. Yang J, Seelig M, Rayner S and **Bredesen DE**. Increasing the proliferative capacity of muscular dystrophy myoblasts. *Muscle Nerve* 1992;**15**:941-948.
25. **Bredesen DE**. Potential role of gene therapy in the treatment of Parkinson's disease. *Neuroscience* 1993;**1**:45-52.
26. Foster LM, Phan T, Verity AN, **Bredesen DE** and Campagnoni AT. Generation and analysis of normal and shiverer temperature-sensitive immortalized cell lines exhibiting phenotypic characteristics of oligodendrocytes at several stages of differentiation. *Dev Neurosci* 1993;**15**:100-109.
27. Kane DJ, Sarafian TA, Anton R, Hahn H, Gralla EB, Valentine JS, Ord T and **Bredesen DE**. Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species. *Science* 1993;**262**:1274-1277.
28. Mah SP, Zhong LT, Liu Y, Roghani A, Edwards RH and **Bredesen DE**. The protooncogene bcl-2 inhibits apoptosis in PC12 cells. *J Neurochem* 1993;**60**:1183-1186.
29. Rabizadeh S, LaCount DJ, Friesen PD and **Bredesen DE**. Expression of the baculovirus p35 gene inhibits mammalian neural cell death. *J Neurochem* 1993;**61**:2318-2321.
30. Rabizadeh S, Oh J, Zhong LT, Yang J, Bitler CM, Butcher LL and **Bredesen DE**. Induction of apoptosis by the low-affinity NGF receptor. *Science* 1993;**261**:345-348.
31. Verity AN, **Bredesen DE**, Vonderscher C, Handley VW and Campagnoni AT. Expression of myelin protein genes and other myelin components in an oligodendrocytic cell line conditionally immortalized with a temperature-sensitive retrovirus. *J Neurochem* 1993;**60**:577-587.
32. Zhong LT, Kane DJ and **Bredesen DE**. BCL-2 blocks glutamate toxicity in neural cell lines. *Brain Res Mol Brain Res* 1993;**19**:353-355.
33. Zhong LT, Sarafian T, Kane DJ, Charles AC, Mah SP, Edwards RH and **Bredesen DE**. bcl-2 inhibits death of central neural cells induced by multiple agents. *Proc Natl Acad Sci U S A* 1993;**90**:4533-4537.
34. Anton R, Kordower JH, Maidment NT, Manaster JS, Kane DJ, Rabizadeh S, Schueller SB, Yang J, Edwards RH, Markham CH and **Bredesen DE**. Neural-targeted gene therapy for rodent and primate hemiparkinsonism. *Exp Neurol* 1994;**127**:207-218.

35. Rabizadeh S, Bitler CM, Butcher LL and **Bredesen DE**. Expression of the low-affinity nerve growth factor receptor enhances ß-amyloid peptide toxicity. *Proc Natl Acad Sci U S A* 1994;**91**:10703-10706.
36. Rabizadeh S and **Bredesen DE**. Is p75NGFR involved in developmental neural cell death? *Dev Neurosci* 1994;**16**:207-211.
37. Sarafian TA and **Bredesen DE.** Is apoptosis mediated by reactive oxygen species? *Free Radic Res* 1994;**21**:1-8.
38. Sarafian TA, Vartavarian L, Kane DJ, **Bredesen DE** and Verity MA. bcl-2 expression decreases methyl mercury-induced free-radical generation and cell killing in a neural cell line. *Toxicol Lett* 1994;**74**:149-155.
39. Anton R, Kordower JH, Kane DJ, Markham CH and **Bredesen DE**. Neural transplantation of cells expressing the anti-apoptotic gene bcl- 2. *Cell Transplant* 1995;**4**:49-54.
40. **Bredesen DE**. Neural apoptosis. *Ann Neurol* 1995;**38**:839-851.
41. Hisanaga K, Kure S, **Bredesen DE,** Ikeda Y, Kohsaka S and Sharp FR. Apoptotic cell death of a temperature-sensitive central neuronal cell line. *Brain Res* 1995;**684**:79-86.
42. Kane DJ, Ord T, Anton R and **Bredesen DE.** Expression of bcl-2 inhibits necrotic neural cell death. *J Neurosci Res* 1995;**40**:269-275.
43. Myers KM, Fiskum G, Liu Y, Simmens SJ, **Bredesen DE** and Murphy AN. Bcl-2 protects neural cells from cyanide/aglycemia-induced lipid oxidation, mitochondrial injury, and loss of viability. *J Neurochem* 1995;**65**:2432-2440.
44. Rabizadeh S, Gralla EB, Borchelt DR, Gwinn R, Valentine JS, Sisodia S, Wong P, Lee M, Hahn H and **Bredesen DE**. Mutations associated with amyotrophic lateral sclerosis convert superoxide dismutase from an antiapoptotic gene to a proapoptotic gene: studies in yeast and neural cells. *Proc Natl Acad Sci U S A* 1995;**92**:3024-3028.
45. Verity MA, **Bredesen DE** and Sarafian T. Role of reactive oxygen species (ROS) in neuronal degeneration. Modulation by protooncogene expression. *Ann N Y Acad Sci* 1995;**765**:340.
46. **Bredesen DE**. Genetic control of neural cell apoptosis. *Perspect Dev Neurobiol* 1996;**3**:101-109.
47. **Bredesen DE**, Wiedau-Pazos M, Goto JJ, Rabizadeh S, Roe JA, Gralla EB, Ellerby LM and Valentine JS. Cell death mechanisms in ALS. *Neurol* 1996;**47**:S36-38; discussion S38-39.
48. Ellerby LM, Ellerby HM, Park SM, Holleran AL, Murphy AN, Fiskum G, Kane DJ, Testa MP, Kayalar C and **Bredesen DE**. Shift of the cellular oxidation-reduction potential in neural cells expressing Bcl-2. *J Neurochem* 1996;**67**:1259-1267.
49. Kayalar C, Ord T, Testa MP, Zhong LT and **Bredesen DE**. Cleavage of actin by interleukin 1 ß-converting enzyme to reverse DNase I inhibition. *Proc Natl Acad Sci U S A* 1996;**93**:2234-2238.
50. Lyons TJ, Liu H, Goto JJ, Nersissian A, Roe JA, Graden JA, Cafe C, Ellerby LM, **Bredesen DE**, Gralla EB and Valentine JS. Mutations in copper-zinc superoxide dismutase that cause amyotrophic lateral sclerosis alter the zinc binding site and the redox behavior of the protein. *proc Natl Acad Sci U S A* 1996;**93**:12240-12244.
51. Murphy AN, **Bredesen DE**, Cortopassi G, Wang E and Fiskum G. Bcl-2 potentiates the maximal calcium uptake capacity of neural cell mitochondria. *Proc Natl Acad Sci U S A* 1996;**93**:9893-9898.

52. Sarafian TA, **Bredesen DE** and Verity MA. Cellular resistance to methylmercury. *Neurotoxicology* 1996;**17**:27-36.
53. Srinivasan A, Foster LM, Testa MP, Ord T, Keane RW, **Bredesen DE** and Kayalar C. Bcl-2 expression in neural cells blocks activation of ICE/CED-3 family proteases during apoptosis. *J Neurosci* 1996;**16**:5654-5660.
54. Wiedau-Pazos M, Goto JJ, Rabizadeh S, Gralla EB, Roe JA, Lee MK, Valentine JS and **Bredesen DE**. Altered reactivity of superoxide dismutase in familial amyotrophic lateral sclerosis. *Science* 1996;**271**:515-518.
55. Wiedau-Pazos M, Trudell JR, Altenbach C, Kane DJ, Hubbell WL and **Bredesen DE**. Expression of bcl-2 inhibits cellular radical generation. *Free Radic Res* 1996;**24**:205-212.
56. **Bredesen DE**, Ellerby LM, Hart PJ, Wiedau-Pazos M and Valentine JS. Do posttranslational modifications of CuZnSOD lead to sporadic amyotrophic lateral sclerosis? *Ann Neurol* 1997;**42**:135-137.
57. **Bredesen DE** and Rabizadeh S. p75NTR and apoptosis: Trk-dependent and Trk-independent effects. *Trends Neurosci* 1997;**20**:287-290.
58. Ellerby HM, Martin SJ, Ellerby LM, Naiem SS, Rabizadeh S, Salvesen GS, Casiano CA, Cashman NR, Green DR and **Bredesen DE**. Establishment of a cell-free system of neuronal apoptosis: comparison of premitochondrial, mitochondrial, and postmitochondrial phases. *J Neurosci* 1997;**17**:6165-6178.
59. Hileman MR, Chapman BS, Rabizadeh S, Krishnan VV, **Bredesen DE**, Assa-Munt N and Plesniak LA. A cytoplasmic peptide of the neurotrophin receptor p75NTR: induction of apoptosis and NMR determined helical conformation. *FEBS Lett* 1997;**415**:145-154.
60. Keane RW, Srinivasan A, Foster LM, Testa MP, Ord T, Nonner D, Wang HG, Reed JC, **Bredesen DE** and Kayalar C. Activation of CPP32 during apoptosis of neurons and astrocytes. *J Neurosci Res* 1997;**48**:168-180.
61. Kruman I, Bruce-Keller AJ, **Bredesen D**, Waeg G and Mattson MP. Evidence that 4-hydroxynonenal mediates oxidative stress-induced neuronal apoptosis. *J Neurosci* 1997;**17**:5089-5100.
62. Longo VD, Ellerby LM, **Bredesen DE**, Valentine JS and Gralla EB. Human Bcl-2 reverses survival defects in yeast lacking superoxide dismutase and delays death of wild-type yeast. *J Cell Biol* 1997;**137**:1581-1588.
63. Ruan Y, Rabizadeh S, Camerini D and **Bredesen DE**. Expression of CD40 induces neural apoptosis. *J Neurosci Res* 1997;**50**:383-390.
64. Yeo TT, Chua-Couzens J, Butcher LL, **Bredesen DE**, Cooper JD, Valletta JS, Mobley WC and Longo FM. Absence of p75NTR causes increased basal forebrain cholinergic neuron size, choline acetyltransferase activity, and target innervation. *J Neurosci* 1997;**17**:7594-7605.
65. **Bredesen DE**, Ye X, Tasinato A, Sperandio S, Wang JJ, Assa-Munt N and Rabizadeh S. p75NTR and the concept of cellular dependence: seeing how the other half die [see comments]. *Cell Death Differ* 1998;**5**:365-371.
66. Bruce-Keller AJ, Begley JG, Fu W, Butterfield DA, **Bredesen DE**, Hutchins JB, Hensley K and Mattson MP. Bcl-2 protects isolated plasma and mitochondrial membranes against lipid peroxidation induced by hydrogen peroxide and amyloid ß-peptide. *J Neurochem* 1998;**70**:31-39.

67. Jurgensmeier JM, Xie Z, Deveraux Q, Ellerby L, **Bredesen D** and Reed JC. Bax directly induces release of cytochrome c from isolated mitochondria. *Proc Natl Acad Sci U S A* 1998;**95**:4997-5002.
68. Martindale D, Hackam A, Wieczorek A, Ellerby L, Wellington C, McCutcheon K, Singaraja R, Kazemi-Esfarjani P, Devon R, Kim SU, **Bredesen DE**, Tufaro F and Hayden MR. Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates. *Nat Genet* 1998;**18**:150-154.
69. Mehlen P, Rabizadeh S, Snipas SJ, Assa-Munt N, Salvesen GS and **Bredesen DE**. The DCC gene product induces apoptosis by a mechanism requiring receptor proteolysis. *Nature* 1998;**395**:801-804.
70. Spear N, Estevez AG, Johnson GV, **Bredesen DE**, Thompson JA and Beckman JS. Enhancement of peroxynitrite-induced apoptosis in PC12 cells by fibroblast growth factor-1 and nerve growth factor requires p21Ras activation and is suppressed by Bcl-2. *Arch Biochem Biophys* 1998;**356**:41-45.
71. Stennicke HR, Jurgensmeier JM, Shin H, deveraux QL, Wolf BB, Yang X, Zhou Q, Ellerby HM, Ellerby LM, **Bredesen D,** Green DR, Reed JC, Froelich CJ and Salvesen GS. Pro-caspase-3 is a major physiologic target of caspase-8. *J Biol Chem* 1998;**273**:27084-27090.
72. Wei H, Wei W, **Bredesen DE** and Perry DC. Bcl-2 protects against apoptosis in neuronal cell line caused by thapsigargin-induced depletion of intracellular calcium stores. *J Neurochem* 1998;**70**:2305-2314.
73. Wellington CL, Ellerby LM, Hackam AS, Margolis RL, Trifiro MA, Singaraja R, McCutcheon K, Salvesen GS, Propp SS, Bromm M, Rowland KJ, Zhang T, Rasper D, Roy S, Thornberry N, Pinsky L, Kakizuka A, **Bredesen, DE**, *et al.* Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. *J Biol Chem* 1998;**273**:9158-9167.
74. **Bredesen DE**. The emerging relationship between developmental and degenerative neural cell death. *Neural Notes* 1999;**70**:31-39.
75. Ellerby HM, Arap W, Ellerby LM, Kain R, Andrusiak R, Rio GD, Krajewski S, Lombardo CR, Rao R, Ruoslahti E, **Bredesen DE** and Pasqualini R. Anti-cancer activity of targeted pro-apoptotic peptides. *Nat Med* 1999;**5**:1032-1038.
76. Ellerby LM, Andrusiak RL, Wellington CL, Hackam AS, Propp SS, Wood JD, Sharp AH, Margolis RL, Ross CA, Salvesen GS, Hayden MR and **Bredesen DE**. Cleavage of atrophin-1 at caspase site aspartic acid 109 modulates cytotoxicity. *J Biol Chem* 1999;**274**:8730-8736.
77. Ellerby LM, Hackam AS, Propp SS, Ellerby HM, Rabizadeh S, Cashman NR, Trifiro MA, Pinsky L, Wellington CL, Salvesen GS, Hayden MR and **Bredesen DE**. Kennedy's disease: caspase cleavage of the androgen receptor is a crucial event in cytotoxicity. *J Neurochem* 1999;**72**:185-195.
78. Hong CS, Caromile L, Nomata Y, Mori H, **Bredesen DE** and Koo EH. Contrasting role of presenilin-1 and presenilin-2 in neuronal differentiation in vitro. *J Neurosci* 1999;**19**:637-643.
79. Irie S, Hachiya T, Rabizadeh S, Maruyama W, Mukai J, Li Y, Reed JC, **Bredesen DE** and Sato TA. Functional interaction of Fas-associated phosphatase-1 (FAP-1) with p75(NTR) and their effect on NF-kappaB activation. *FEBS Lett* 1999;**460**:191-198.

80. Krajewski S, Krajewska M, Ellerby LM, Welsh K, Xie Z, Deveraux QL, Salvesen GS, **Bredesen DE**, Rosenthal RE, Fiskum G and Reed JC. Release of caspase-9 from mitochondria during neuronal apoptosis and cerebral ischemia. *Proc Natl Acad Sci U S A* 1999;**96**:5752-5757.
81. Rabizadeh S, Ye X, Wang JJ and **Bredesen DE**. Neurotrophin dependence mediated by p75NTR : contrast between rescue by BDNF and NGF. *Cell Death Differ* 1999;**6**:1222-1227.
82. Ye X, Mehlen P, Rabizadeh S, VanArsdale T, Zhang H, Shin H, Wang JJ, Leo E, Zapata J, Hauser CA, Reed JC and **Bredesen DE**. TRAF family proteins interact with the common neurotrophin receptor and modulate apoptosis induction. *J Biol Chem* 1999;**274**:30202-30208.
83. Bordeaux MC, Forcet C, Granger L, Corset V, Bidaud C, Billaud M, **Bredesen DE**, Edery P and Mehlen P. The RET proto-oncogene induces apoptosis: a novel mechanism for Hirschsprung disease. *Embo J* 2000;**19**:4056-4063.
84. **Bredesen DE**. Apoptosis: overview and signal transduction pathways. *J Neurotrauma* 2000;**17**:801-810.
85. Cafe C, Testa MP, Sheldon PJ, French WP, Ellerby LM and **Bredesen DE**. Loss of oxidation-reduction specificity in amyotrophic lateral sclerosis-associated CuZnSOD mutants. *J Mol Neurosci* 2000;**15**:71-83.
86. Ellerby LM and **Bredesen DE**. Measurement of cellular oxidation, reactive oxygen species, and antioxidant enzymes during apoptosis. *Methods Enzymol* 2000;**322**:413-421.
87. Kelner GS, Lee M, Clark ME, Maciejewski D, McGrath D, Rabizadeh S, Lyons T, **Bredesen D**, Jenner P and Maki RA. The copper transport protein Atox1 promotes neuronal survival. *J Biol Chem* 2000;**275**:580-584.
88. Kluck RM, Ellerby LM, Ellerby HM, Naiem S, Yaffe MP, Margoliash E, **Bredesen D**, Mauk AG, Sherman F and Newmeyer DD. Determinants of cytochrome c pro-apoptotic activity. The role of lysine 72 trimethylation. *J Biol Chem* 2000;**275**:16127-16133.
89. Lu DC, Rabizadeh S, Chandra S, Shayya RF, Ellerby LM, Ye X, Salvesen GS, Koo EH and **Bredesen DE**. A second cytotoxic proteolytic peptide derived from amyloid beta-protein precursor. *Nat Med* 2000;**6**:397-404.
90. Mehlen P and **Bredesen DE**. [Dependence receptors: links between apoptosis, nervous system development and control of tumorigenesis]. *Bull Cancer* 2000;**87**:537-541.
91. Rabizadeh S, Ye X, Sperandio S, Wang JJ, Ellerby HM, Ellerby LM, Giza C, Andrusiak RL, Frankowski H, Yaron Y, Moayeri NN, Rovelli G, Evans CJ, Butcher LL, Nolan GP, Assa-Munt N and **Bredesen DE**. Neurotrophin dependence domain: a domain required for the mediation of apoptosis by the p75 neurotrophin receptor. *J Mol Neurosci* 2000;**15**:215-229.
92. Sperandio S, de Belle I and **Bredesen DE**. An alternative, non-apoptotic form of programmed cell death. *Proc Natl Acad Sci U S A* 2000;**97**:14376-14381.
93. Wang JJ, Rabizadeh S, Tasinato A, Sperandio S, Ye X, Green M, Assa-Munt N, Spencer D and **Bredesen DE**. Dimerization-dependent block of the proapoptotic effect of P75(NTR). *J Neurosci Res* 2000;**60**:587-593.
94. Wang JJ, Tasinato A, Ethell DW, Testa MP and **Bredesen DE**. Phosphorylation of the common neurotrophin receptor p75 by p38ß2 kinase affects NF-kB and AP-1 activities. *J Mol Neurosci* 2000;**15**:19-29.

95. Wei H, Leeds P, Chen RW, Wei W, Leng Y, **Bredesen DE** and Chuang DM. Neuronal apoptosis induced by pharmacological concentrations of 3- hydroxykynurenine: characterization and protection by dantrolene and Bcl-2 overexpression. *J Neurochem* 2000;**75**:81-90.
96. Wellington CL, Singaraja R, Ellerby L, Savill J, Roy S, Leavitt B, Cattaneo E, Hackam A, Sharp A, Thornberry N, Nicholson DW, **Bredesen DE** and Hayden MR. Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells. *J Biol Chem* 2000;**275**:
97. **Bredesen DE**. Neurodegenerative disease and cancer: two sides of a coin? *Hosp Pract (Off Ed)* 2001;**36**:39-42, 45.
98. del Rio G, Bartley TF, del-Rio H, Rao R, Jin K, Greenberg DA, Eshoo M and **Bredesen DE**. Mining DNA microarray data using a novel approach based on graph theory. *FEBS Lett* 2001;**509**:230-234.
99. del Rio G, Castro-Obregon S, Rao R, Ellerby HM and **Bredesen DE**. APAP, a sequence-pattern recognition approach identifies substance P as a potential apoptotic peptide. *FEBS Lett* 2001;**494**:213-219.
100. Ethell DW, Bossy-Wetzel E and **Bredesen DE.** Caspase 7 can cleave tumor necrosis factor receptor-I (p60) at a non- consensus motif, in vitro. *Biochim Biophys Acta* 2001;**1541**:231-238.
101. Forcet C, Ye X, Granger L, Corset V, Shin H, **Bredesen DE** and Mehlen P. The dependence receptor DCC (deleted in colorectal cancer) defines an alternative mechanism for caspase activation. *Proc Natl Acad Sci U S A* 2001;**98**:3416-3421.
102. Gerlag DM, Borges E, Tak PP, Ellerby HM, **Bredesen DE**, Pasqualini R, Ruoslahti E and Firestein GS. Suppression of murine collagen-induced arthritis by targeted apoptosis of synovial neovasculature. *Arthritis Res* 2001;**3**:357-361.
103. Lee M, Hyun DH, Marshall KA, Ellerby LM, **Bredesen DE**, Jenner P and Halliwell B. Effect of overexpression of Bcl-2 on cellular oxidative damage, nitric oxide production, antioxidant defenses, and the proteasome. *Free Radic Biol Med* 2001;**31**:1550-1559.
104. Lee S, Furuya T, Kiyota T, Takami N, Murata K, Niidome Y, **Bredesen DE**, Ellerby HM and Sugihara G. De novo-designed peptide transforms Golgi-specific lipids into Golgi- like nanotubules. *J Biol Chem* 2001;**276**:41224-41228.
105. Peel AL, Rao RV, Cottrell BA, Hayden MR, Ellerby LM and **Bredesen DE**. Double-stranded RNA-dependent protein kinase, PKR, binds preferentially to Huntington's disease (HD) transcripts and is activated in HD tissue. *Hum Mol Genet* 2001;**10**:1531-1538.
106. Rao RV, Hermel E, Castro-Obregon S, del Rio G, Ellerby LM, Ellerby HM and **Bredesen DE**. Coupling endoplasmic reticulum stress to the cell death program. Mechanism of caspase activation. *J Biol Chem* 2001;**276**:33869-33874.
107. Stoka V, Turk B, Schendel SL, Kim TH, Cirman T, Snipas SJ, Ellerby LM, **Bredesen D,** Freeze H, Abrahamson M, Bromme D, Krajewski S, Reed JC, Yin XM, Turk V and Salvesen GS. Lysosomal protease pathways to apoptosis. Cleavage of bid, not pro-caspases, is the most likely route. *J Biol Chem* 2001;**276**:3149-3157.
108. Zhong LT, Manzi A, Skowronski E, Notterpek L, Fluharty AL, Faull KF, Masada I, Rabizadeh S, Varsanyi-Nagy M, Ruan Y, Oh JD, Butcher LL and **Bredesen DE**. A monoclonal antibody that induces neuronal apoptosis binds a metastasis marker. *Cancer Res* 2001;**61**:5741-5748.

109. Arap W, Haedicke W, Bernasconi M, Kain R, Rajotte D, Krajewski S, Ellerby HM, **Bredesen DE**, Pasqualini R and Ruoslahti E. Targeting the prostate for destruction through a vascular address. *Proc Natl Acad Sci U S A* 2002;**99**:1527-1531.
110. Castro-Obregon S, Del Rio G, Chen SF, Swanson RA, Frankowski H, Rao RV, Stoka V, Vesce S, Nicholls DG and **Bredesen DE**. A ligand-receptor pair that triggers a non-apoptotic form of programmed cell death. *Cell Death Differ* 2002;**9**:807-817.
111. Frankowski H, Castro-Obregon S, del Rio G, Rao RV and **Bredesen DE**. PLAIDD, a type II death domain protein that interacts with p75 neurotrophin receptor. *Neuromolecular Med* 2002;**1**:153-170.
112. Galvan V, Chen S, Lu D, Logvinova A, Goldsmith P, Koo EH and **Bredesen DE**. Caspase cleavage of members of the amyloid precursor family of proteins. *J Neurochem* 2002;**82**:283-294.
113. Kurakin A and **Bredesen D**. Target-assisted iterative screening reveals novel interactors for PSD95, Nedd4, Src, Abl and Crk proteins. *J Biomol Struct Dyn* 2002;**19**:1015-1029.
114. Rao RV, Castro-Obregon S, Frankowski H, Schuler M, Stoka V, del Rio G, **Bredesen DE** and Ellerby HM. Coupling endoplasmic reticulum stress to the cell death program. An Apaf-1-independent intrinsic pathway. *J Biol Chem* 2002;**277**:21836-21842.
115. Rao RV, Peel A, Logvinova A, del Rio G, Hermel E, Yokota T, Goldsmith PC, Ellerby LM, Ellerby HM and **Bredesen DE.** Coupling endoplasmic reticulum stress to the cell death program: role of the ER chaperone GRP78. *FEBS Lett* 2002;**514**:122-128.
116. Wellington CL, Ellerby LM, Gutekunst CA, Rogers D, Warby S, Graham RK, Loubser O, van Raamsdonk J, Singaraja R, Yang YZ, Gafni J, **Bredesen D**, Hersch SM, Leavitt BR, Roy S, Nicholson DW and Hayden MR. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease. *J Neurosci* 2002;**22**:7862-7872.
117. Ellerby HM, Lee S, Ellerby LM, Chen S, Kiyota T, del Rio G, Sugihara G, Sun Y, **Bredesen DE**, Arap W and Pasqualini R. An artificially designed pore-forming protein with anti-tumor effects. *J Biol Chem* 2003;**278**:35311-35316.
118. Galvan V, Logvinova A, Sperandio S, Ichijo H and **Bredesen DE**. Type 1 insulin-like growth factor receptor (IGF-IR) signaling inhibits apoptosis signal-regulating kinase 1 (ASK1). *J Biol Chem* 2003;**278**:13325-13332.
119. Kurakin AV, Wu S and **Bredesen DE**. Atypical recognition consensus of CIN85/SETA/Ruk SH3 domains revealed by target-assisted iterative screening. *J Biol Chem* 2003;**278**:34102-34109.
120. Lu DC, Shaked GM, Masliah E, **Bredesen DE** and Koo EH. Amyloid beta protein toxicity mediated by the formation of amyloid-beta protein precursor complexes. *Ann Neurol* 2003;**54**:781-789.
121. Lu DC, Soriano S, **Bredesen DE** and Koo EH. Caspase cleavage of the amyloid precursor protein modulates amyloid beta-protein toxicity. *J Neurochem* 2003;**87**:733-741.
122. Mehlen P and **Bredesen DE**. Meeting report: cellular dependence--old concept, new mechanisms. *Sci STKE* 2003;**2003**:pe55.
123. Peel AL and **Bredesen DE**. Activation of the cell stress kinase PKR in Alzheimer's disease and human amyloid precursor protein transgenic mice. *Neurobiol Dis* 2003;**14**:52-62.
124. Rabizadeh S and **Bredesen DE**. Ten years on: mediation of cell death by the common neurotrophin receptor p75(NTR). *Cytokine Growth Factor Rev* 2003;**14**:225-239.
125. **Bredesen DE**. Rebuttal to Austad: 'Is aging programmed? *Aging Cell* 2004;**3**:261-262.

126. **Bredesen DE**. Toward a mechanistic taxonomy of cell death programs. *J Alzheimers Dis* 2004;**6**:S3-6.
127. **Bredesen DE**. The non-existent aging program: how does it work? *Aging Cell* 2004;**3**:255-259.
128. **Bredesen DE,** Mehlen P and Rabizadeh S. Apoptosis and dependence receptors: a molecular basis for cellular addiction. *Physiol Rev* 2004;**84**:411-430.
129. Castro-Obregon S, Rao RV, del Rio G, Chen SF, Poksay KS, Rabizadeh S, Vesce S, Zhang XK, Swanson RA and **Bredesen DE**. Alternative, nonapoptotic programmed cell death: mediation by arrestin 2, ERK2, and Nur77. *J Biol Chem* 2004;**279**:17543-17553.
130. Galvan V, Kurakin AV and **Bredesen DE**. Interaction of checkpoint kinase 1 and the X-linked inhibitor of apoptosis during mitosis. *FEBS Lett* 2004;**558**:57-62.
131. Hashimoto Y, Kaneko Y, Tsukamoto E, Frankowski H, Kouyama K, Kita Y, Niikura T, Aiso S, **Bredesen DE**, Matsuoka M and Nishimoto I. Molecular characterization of neurohybrid cell death induced by Alzheimer's amyloid-beta peptides via p75NTR/PLAIDD. *J Neurochem* 2004;**90**:549-558.
132. Hermel E, Gafni J, Propp SS, Leavitt BR, Wellington CL, Young JE, Hackam AS, Logvinova AV, Peel AL, Chen SF, Hook V, Singaraja R, Krajewski S, Goldsmith PC, Ellerby HM, Hayden MR, **Bredesen DE**, *et al.* Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease. *Cell Death Differ* 2004;**11**:424-438.
133. Jin K, Galvan V, Xie L, Mao XO, Gorostiza OF, **Bredesen DE** and Greenberg DA. Enhanced neurogenesis in Alzheimer's disease transgenic (PDGF-APPSw,Ind) mice. *Proc Natl Acad Sci U S A* 2004;**101**:13363-13367.
134. Kurakin A, Wu S and **Bredesen DE**. Target-assisted iterative screening of phage surface display cDNA libraries. *Methods Mol Biol* 2004;**264**:47-60.
135. Mazelin L, Bernet A, Bonod-Bidaud C, Pays L, Arnaud S, Gespach C, **Bredesen DE**, Scoazec JY and Mehlen P. Netrin-1 controls colorectal tumorigenesis by regulating apoptosis. *Nature* 2004;**431**:80-84.
136. Mehlen P and **Bredesen DE**. The dependence receptor hypothesis. *Apoptosis* 2004;**9**:37-49.
137. Peel AL, Sorscher N, Kim JY, Galvan V, Chen S and **Bredesen DE**. Tau Phosphorylation in Alzheimer's Disease: Potential Involvement of an APP-MAP Kinase Complex. *Neuromolecular Med* 2004;**5**:205-218.
138. Rao RV and **Bredesen DE**. Misfolded proteins, endoplasmic reticulum stress and neurodegeneration. *Curr Opin Cell Biol* 2004;**16**:653-662.
139. Rao RV, Ellerby HM and **Bredesen DE**. Coupling endoplasmic reticulum stress to the cell death program. *Cell Death Differ* 2004;**11**:372-380.
140. Rao RV, Poksay KS, Castro-Obregon S, Schilling B, Row RH, del Rio G, Gibson BW, Ellerby HM and **Bredesen DE**. Molecular components of a cell death pathway activated by endoplasmic reticulum stress. *J Biol Chem* 2004;**279**:177-187.
141. Sperandio S, Poksay K, de Belle I, Lafuente MJ, Liu B, Nasir J and **Bredesen DE**. Paraptosis: mediation by MAP kinases and inhibition by AIP-1/Alix. *Cell Death Differ* 2004;**11**:1066-1075.

142. Yokota T, Miyagishi M, Hino T, Matsumura R, Tasinato A, Urushitani M, Rao RV, Takahashi R, **Bredesen DE**, Taira K and Mizusawa H. siRNA-based inhibition specific for mutant SOD1 with single nucleotide alternation in familial ALS, compared with ribozyme and DNA enzyme. *Biochem Biophys Res Commun* 2004;**314**:283-291.
143. **Bredesen DE**, Mehlen P and Rabizadeh S. Receptors that mediate cellular dependence. *Cell Death Differ* 2005;**12**:1031-1043.
144. Cottrell BA, Galvan V, Banwait S, Gorostiza O, Lombardo CR, Williams T, Schilling B, Peel A, Gibson B, Koo EH, Link CD and **Bredesen DE**. A pilot proteomic study of amyloid precursor interactors in Alzheimer's disease. *Ann Neurol* 2005;**58**:277-289.
145. Stoka V, Chen SF, Turk V and **Bredesen DE**. Developmental shift in the apostat: Comparison of neurones and astrocytes. *FEBS Lett* 2005;**579**:6147-6150.
146. Thibert B, **Bredesen DE** and del Rio G. Improved prediction of critical residues for protein function based on network and phylogenetic analyses. *BMC Bioinformatics* 2005;**6**:213.
147. Warner H, Anderson J, Austad S, Bergamini E, **Bredesen D**, Butler R, Carnes BA, Clark BF, Cristofalo V, Faulkner J, Guarente L, Harrison DE, Kirkwood T, Lithgow G, Martin G, Masoro E, Melov S, *et al.* Science fact and the SENS agenda. What can we reasonably expect from ageing research? *EMBO Rep* 2005;**6**:1006-1008.
148. **Bredesen DE**, Rao RV and Mehlen P. Cell death in the nervous system. *Nature* 2006;**443**:796-802.
149. Galvan V, Gorostiza OF, Banwait S, Ataie M, Logvinova AV, Sitaraman S, Carlson E, Sagi SA, Chevallier N, Jin K, Greenberg DA and **Bredesen DE**. Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664. *Proc Natl Acad Sci U S A* 2006;**103**:7130-7135.
150. Rao RV, Niazi K, Mollahan P, Mao X, Crippen D, Poksay KS, Chen S and **Bredesen DE**. Coupling endoplasmic reticulum stress to the cell-death program: a novel HSP90-independent role for the small chaperone protein p23. *Cell Death Differ* 2006;**13**:415-425.
151. Saganich MJ, Schroeder BE, Galvan V, **Bredesen DE,** Koo EH and Heinemann SF. Deficits in synaptic transmission and learning in amyloid precursor protein (APP) transgenic mice require C-terminal cleavage of APP. *J Neurosci* 2006;**26**:13428-13436.
152. Shaked GM, Kummer MP, Lu DC, Galvan V, **Bredesen DE** and Koo EH. Abeta induces cell death by direct interaction with its cognate extracellular domain on APP (APP 597-624). *FASEB J* 2006;**20**:1254-1256.
153. Stoka V, Turk V and **Bredesen DE**. Differential regulation of the intrinsic pathway of apoptosis in brain and liver during ageing. *FEBS Lett* 2006;**580**:3739-3745.
154. **Bredesen DE**. Key note lecture: toward a mechanistic taxonomy for cell death programs. *Stroke* 2007;**38**:652-660.
155. **Bredesen DE** and Rabizadeh S. APP-based neuroprotective strategies. *Curr Alzheimer Res* 2007;**4**:541-543.
156. Cusack MP, Thibert B, **Bredesen DE** and Del Rio G. Efficient identification of critical residues based only on protein structure by network analysis. *PLoS One* 2007;**2**:e421.
157. del Rio G, Kane DJ, Ball KD and **Bredesen DE**. A novel motif identified in dependence receptors. *PLoS One* 2007;**2**:e463.
158. Egger L, Madden DT, Rheme C, Rao RV and **Bredesen DE**. Endoplasmic reticulum stress-induced cell death mediated by the proteasome. *Cell Death Differ* 2007;**14**:1172-1180.

159. Galvan V, Banwait S, Spilman P, Gorostiza OF, Peel A, Ataie M, Crippen D, Huang W, Sidhu G, Ichijo H and **Bredesen DE**. Interaction of ASK1 and the beta-amyloid precursor protein in a stress-signaling complex. *Neurobiol Dis* 2007;**28**:65-75.
160. Galvan V and **Bredesen DE**. Neurogenesis in the adult brain: implications for Alzheimer's disease. *CNS Neurol Disord Drug Targets* 2007;**6**:303-310.
161. Kurakin A and **Bredesen DE**. An unconventional IAP-binding motif revealed by target-assisted iterative screening (TAIS) of the BIR3-cIAP1 domain. *J Mol Recognit* 2007;**20**:39-50.
162. Kurakin A, Swistowski A, Wu SC and **Bredesen DE**. The PDZ domain as a complex adaptive system. *PLoS One* 2007;**2**:e953.
163. Levy RM, **Bredesen DE** and Rosenblum ML. Neurological manifestations of the acquired immunodeficiency syndrome (AIDS): experience at UCSF and review of the literature. 1985. *J Neurosurg* 2007;**107**:1253-1273; discussion 1251.
164. Madden DT, Egger L and **Bredesen DE**. A calpain-like protease inhibits autophagic cell death. *Autophagy* 2007;**3**:519-522.
165. Stoka V, Turk V and **Bredesen DE**. Differential regulation of Smac/DIABLO and Hsp-70 during brain maturation. *Neuromolecular Med* 2007;**9**:255-263.
166. Young JE, Gouw L, Propp S, Sopher BL, Taylor J, Lin A, Hermel E, Logvinova A, Chen SF, Chen S, **Bredesen DE**, Truant R, Ptacek LJ, La Spada AR and Ellerby LM. Proteolytic cleavage of ataxin-7 by caspase-7 modulates cellular toxicity and transcriptional dysregulation. *J Biol Chem* 2007;**282**:30150-30160.
167. Bakhshi J, Weinstein L, Poksay KS, Nishinaga B, **Bredesen DE** and Rao RV. Coupling endoplasmic reticulum stress to the cell death program in mouse melanoma cells: effect of curcumin. *Apoptosis* 2008;**13**:904-914.
168. Banwait S, Galvan V, Zhang J, Gorostiza OF, Ataie M, Huang W, Crippen D, Koo EH and **Bredesen DE**. C-terminal cleavage of the amyloid-beta protein precursor at Asp664: a switch associated with Alzheimer's disease. *J Alzheimers Dis* 2008;**13**:1-16.
169. **Bredesen DE.** Programmed cell death mechanisms in neurological disease. *Curr Mol Med* 2008;**8**:173-186.
170. Chinta SJ, Rane A, Poksay KS, **Bredesen DE**, Andersen JK and Rao RV. Coupling endoplasmic reticulum stress to the cell death program in dopaminergic cells: effect of paraquat. *Neuromolecular Med* 2008;**10**:333-342.
171. Ellerby HM, **Bredesen DE**, Fujimura S and John V. Hunter-killer peptide (HKP) for targeted therapy. *J Med Chem* 2008;**51**:5887-5892.
172. Galvan V, Zhang J, Gorostiza OF, Banwait S, Huang W, Ataie M, Tang H and **Bredesen DE**. Long-term prevention of Alzheimer's disease-like behavioral deficits in PDAPP mice carrying a mutation in Asp664. *Behav Brain Res* 2008;**191**:246-255.
173. Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, Askew DS, Baba M, Baehrecke EH, Bahr BA, Ballabio A, Bamber BA, Bassham DC, Bergamini E, Bi X, Biard-Piechaczyk M, Blum JS, **Bredesen DE**, *et al.* Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. *Autophagy* 2008;**4**:151-175.
174. Nguyen TV, Galvan V, Huang W, Banwait S, Tang H, Zhang J and **Bredesen DE**. Signal transduction in Alzheimer disease: p21-activated kinase signaling requires C-terminal cleavage of APP at Asp664. *J Neurochem* 2008;**104**:1065-1080.

175. Rossi D, Brambilla L, Valori CF, Roncoroni C, Crugnola A, Yokota T, **Bredesen DE** and Volterra A. Focal degeneration of astrocytes in amyotrophic lateral sclerosis. *Cell Death Differ* 2008;**15**:1691-1700.
176. **Bredesen DE.** Neurodegeneration in Alzheimer's disease: caspases and synaptic element interdependence. *Mol Neurodegener* 2009;**4**:27.
177. Chinta SJ, Poksay KS, Kaundinya G, Hart M, **Bredesen DE**, Andersen JK and Rao RV. Endoplasmic reticulum stress-induced cell death in dopaminergic cells: effect of resveratrol. *J Mol Neurosci* 2009;**39**:157-168.
178. Fombonne J, Rabizadeh S, Banwait S, Mehlen P and **Bredesen DE**. Selective vulnerability in Alzheimer's disease: amyloid precursor protein and p75(NTR) interaction. *Ann Neurol* 2009;**65**:294-303.
179. Galluzzi L, Aaronson SA, Abrams J, Alnemri ES, Andrews DW, Baehrecke EH, Bazan NG, Blagosklonny MV, Blomgren K, Borner C, **Bredesen DE**, Brenner C, Castedo M, Cidlowski JA, Ciechanover A, Cohen GM, De Laurenzi V, *et al.* Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. *Cell Death Differ* 2009;**16**:1093-1107.
180. Lourenco FC, Galvan V, Fombonne J, Corset V, Llambi F, Muller U, **Bredesen DE** and Mehlen P. Netrin-1 interacts with amyloid precursor protein and regulates amyloid-beta production. *Cell Death Differ* 2009;**16**:655-663.
181. Mille F, Llambi F, Guix C, Delloye-Bourgeois C, Guenebeaud C, Castro-Obregon S, **Bredesen DE**, Thibert C and Mehlen P. Interfering with multimerization of netrin-1 receptors triggers tumor cell death. *Cell Death Differ* 2009;**16**:1344-1351.
182. Park SA, Shaked GM, **Bredesen DE** and Koo EH. Mechanism of cytotoxicity mediated by the C31 fragment of the amyloid precursor protein. *Biochem Biophys Res Commun* 2009;**388**:450-455.
183. Swistowski A, Zhang Q, Orcholski ME, Crippen D, Vitelli C, Kurakin A and **Bredesen DE**. Novel mediators of amyloid precursor protein signaling. *J Neurosci* 2009;**29**:15703-15712.
184. Vogt DL, Thomas D, Galvan V, **Bredesen DE**, Lamb BT and Pimplikar SW. Abnormal neuronal networks and seizure susceptibility in mice overexpressing the APP intracellular domain. *Neurobiol Aging* 2009;
185. Butterfield DA, Galvan V, Lange MB, Tang H, Sowell RA, Spilman P, Fombonne J, Gorostiza O, Zhang J, Sultana R and **Bredesen DE.** In vivo oxidative stress in brain of Alzheimer disease transgenic mice: Requirement for methionine 35 in amyloid beta-peptide of APP. *Free Radic Biol Med* 2010;**48**:136-144.
186. Harris JA, Devidze N, Halabisky B, Lo I, Thwin MT, Yu GQ, **Bredesen DE**, Masliah E and Mucke L. Many neuronal and behavioral impairments in transgenic mouse models of Alzheimer's disease are independent of caspase cleavage of the amyloid precursor protein. *J Neurosci* 2010;**30**:372-381.
187. Spilman P, Podlutskaya N, Hart MJ, Debnath J, Gorostiza O, **Bredesen D**, Richardson A, Strong R and Galvan V. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. *PLoS One* 2010;**5**:e9979.

188. Zhang J, Gorostiza OF, Tang H, **Bredesen DE** and Galvan V. Reversal of learning deficits in hAPP transgenic mice carrying a mutation at Asp664: a role for early experience. *Behav Brain Res* 2010;**206**:202-207.
189. Sperandio S., Poksay, KS, Schilling B, Crippen D, Gibson BW, **Bredesen DE**. Identification of new modulators and protein alterations in non-apoptotic programmed cell death. J Cell Biochem.2010 Dec 15; 111(6): 1401-12. doi 10.1002/jcb.22870
190. **Bredesen DE**, John V, Galvan V. Importance of the caspase cleavage site in amyloid-β protein precursor. J Alzheimers Disease 2010; 22(1):57-63
191. Descamps, O, Zhang, Q, John V, **Bredesen DE** Induction of the C-Terminal Proteolytic Cleavage of AβPP by Statins. J Alzheimers Dis. 2011 Mar 18. [Epub ahead of print]
192. Mehlen, P, **Bredesen, D.E**. Dependence receptors: from basic research to drug development. Sci Sign 2011 Jan. 25; 4(157):mr2
193. Poksay, KS, Madden DR, Peter AK, Niazi, K, Banwait, S, Crippen D, **Bredese DE**, Rao RV. Valosin-containing protein gene mutations: cellular phenotypes relevant to neurodegeneration J Mol Neurosci, 2011 Jun: 44(2): 91012 Epub 2011 Jan. 20
194. Orcholski, ME, Zhang, Q, **Bredesen DE**. Signaling via amyloid precursor-like proteins APLP1 and APLP2. J Alzheimers Dis 2011: 23(4):689-99
195. Robinson, R.A., Lange, MB, Sultana, R., Galvan, V, Fombonne, J., Gorostiza, O, Zhang, J.,Warrier, G., Cai, J. Pierce, W.M., **Bredesen, D.E**., Differential expression and redox proteomics analyses of an Alzheimer disease transgenic mouse model: effects of the amyloid-beta peptide of amyloid precursor protein(Xi). *Neuroscience* **177**, 207-222, (2011).
196. Poksay, K.S., Banwait, S., Crippen D., Mao, X, **Bredesen, D.E**., Rao RV The Small Chaperone Protein p23 and Its Cleaved Product p19 in Cellular Stress. *J Mol Neurosci*, 9574-7 (2011).
197. Zhang, J, Rao, RV, Spilman P, Mangada J, Xie L, Vitelli, C, Gorostiza, OF, Madden DT, Zeng X, Jin K, Hart, MJ, **Bredesen, DE**, Galvan, V., Endogenously EGFP-Labeled Mouse Embryonic Stem Cells. *Aging Dis* **2**, 18-29 (2011)
198. Madden D.T., Davila-Kruger D, Melov S, **Bredesen D.E**., Human Embryonic Stem Cells Express Elevated Levels of Multiple Pro-Apoptotic BCL-2 Family Members., *PLoS One* **6**, e28530, 10.1371/journal.pone.0028530 PONE-D-11-19250 (2011).
199. Libeu CP, Poksay K., John V, **Bredesen DE**, Structural and Functional Alterations in Amyloid-B Precursor Protein Induced by Amyloid-B Peptides, *J Alzheimers Dis* **25**, 547-566, (2011)
200. Rao, R., Patent, A., Zhang, Q., Flores, S., **Bredesen, D.E**., 2011. Cellular effects of APOE4: Implications for Alzheimer's disease. Alzheimer's & Dementia: The Journal of the Alzheimer's Association. Vol. 7**,** S569.
201. Libeu CP, Descamps O, Zhang J, John V, **Bredesen DE**, Altering APP proteolysis: increasing sAPPalpha by targeting dimerization of the APP ectodomain, PLoS One 2012
202. Choi SW, G.A., Ng R, Flynn JM, Melov S, Danielson SR, Gibson BW, Nicholls DG, **Bredesen DE**, Brand MD., 2012 Nov. 21. No consistent bioenergetic defects in presynaptic nerve terminals isolated from mouse models of Alzheimer's disease. Journal of Neuroscience. 32(47):16775-84. doi: 10.1523/JNEUROSCI.2414-12.2012.
203. Rao, R., Descamps, O., John, V, **Bredesen DE**, Ayurvedic medicinal plants for Alzheimer's disease: a review. Alzheimer's Research & Therapy 2012

204. Jonathan G Rodríguez Plaza, Amanda Villalón Rojas, Sur Herrera, Georgina Garza-Ramos, Alfredo Torres Larios, Carlos Amero, Gabriela Zarraga Granados, Manuel Gutiérrez Aguilar, María Teresa Lara Ortiz, Carlos Polanco Gonzalez, Salvador Uribe Carvajal, Roberto Coria, Antonio Peña Díaz, **Dale E Bredesen**, Susana Castro-Obregon, Gabriel Del Rio (2012) "Moonlighting peptides with emerging function." PLoS ONE, 7:7 e40125
205. Sultana R, R.R., Lange MB, Fiorini A, Galvan V, Fombonne J, Baker A, Gorostiza O, Zhang J, Cai J, Pierce WM, **Bredesen DE**, Butterfield DA., 2012. Do proteomics analyses provide insights into reduced oxidative stress in the brain of an Alzheimer disease transgenic mouse model with an M631L amyloid precursor protein substitution and thereby the importance of amyloid-beta-resident methionine 35 in Alzheimer disease pathogenesis? Antioxid Redox Signal. . 17(11):1507-14. Epub 2012 Jun 6.
206. Poksay, K.S., Banwait, S., Crippen, D., Mao, X., **Bredesen, D.E**., Rao, R.V., 2012. The small chaperone protein p23 and its cleaved product p19 in cellular stress. J Mol Neurosci. 46**,** 303-14.
207. **Bredesen, D.E**., John, V., 2013. Next generation therapeutics for Alzheimer's disease. EMBO Mol Med. 5**,** 795-8.
208. Descamps, O., Spilman, P., Zhang, Q., Libeu, C.P., Poksay, K., Gorostiza, O., Campagna, J., Jagodzinska, B., **Bredesen, D.E**., John, V., 2013. AbetaPP-Selective BACE Inhibitors (ASBI): Novel Class of Therapeutic Agents for Alzheimer's Disease. J Alzheimers Dis. 2013;37(2):343-55. doi: 10.3233/JAD-130578.
209. Zhang, J., Spilman, P., Chen, S., Gorostiza, O., Matalis, A., Niazi, K., **Bredesen, D.E.,** Rao, R.V., 2013. The small co-chaperone p23 overexpressing transgenic mouse. J Neurosci Methods. 212**,** 190-4.
210. Theendakara, V., Patent, A., Peters-Libeu, C., Philpot, B., Flores, S., Descamps, O., Poksay, K., Zhang, Q., Cailing, G., Hart, M., John, V., Rao, R., **Bredesen, D**., Neuroprotective sirtuin ratio reversed by ApoE4. PNAS 2013 Nov 5;110(45):18303-8. doi: 10.1073/pnas.1314145110. Epub 2013 Oct 21
211. Spilman, P., Descamps, O., Gorostiza, O., Peters-Libeu, C., Poksay, K., Matalis, A., Patent, A., Rao, R., John, V., **Bredesen, D**., *The multi-functional drug tropisetron binds APP and normalizes cognition in a murine Alzheimer's mod*el Brain Research Journal 2014 March 10
212. Zhang, Q., Descamps, O., Hart, M.J., Poksay, K., Spilman, P., Kane, D., Gorostiza, O., John, V., **Bredesen, D.E**., Paradoxical Effect of TrkA Inhibition in Alzheimer's Disease Models. J. Alzheimer's Disease 2014 Feb. 14 (Submitted)
213. Galluzzi L, Bravo-San Pedro JM, Vitale I, Aaronson SA, Abrams JM, Adam D, Alnemri ES, Altucci L, Andrews D, Annicchiarico-Petruzzelli M, Baehrecke EH, Bazan NG, Bertrand MJ, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, **Bredesen DE,** Brenner C, Campanella M, Candi E, Cecconi F, Chan FK, Chandel NS, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Dawson TM, Dawson VL, De Laurenzi V, De Maria R, Debatin KM, Di Daniele N, Dixit VM, Dynlacht BD, El-Deiry WS, Fimia GM, Flavell RA, Fulda S, Garrido C, Gougeon ML, Green DR, Gronemeyer H, Hajnoczky G, Hardwick JM, Hengartner MO, Ichijo H, Joseph B, Jost PJ, Kaufmann T, Kepp O, Klionsky DJ, Knight RA, Kumar S, Lemasters JJ, Levine B, Linkermann A, Lipton SA, Lockshin RA, López-Otín C, Lugli E, Madeo F, Malorni W, Marine JC, Martin SJ,

Martinou JC, Medema JP, Meier P, Melino S, Mizushima N, Moll U, Muñoz-Pinedo C, Nuñez G, Oberst A, Panaretakis T, Penninger JM, Peter ME, Piacentini M, Pinton P, Prehn JH, Puthalakath H, Rabinovich GA, Ravichandran KS, Rizzuto R, Rodrigues CM, Rubinsztein DC, Rudel T, Shi Y, Simon HU, Stockwell BR, Szabadkai G, Tait SW, Tang HL, Tavernarakis N, Tsujimoto Y, Vanden Berghe T, Vandenabeele P, Villunger A, Wagner EF, Walczak H, White E, Wood WG, Yuan J, Zakeri Z, Zhivotovsky B, Melino G, Kroemer G. Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. Cell Death Differ. 2015 Jan;22 (1) : 58-73.

214. **Bredesen DE**. Reversal of cognitive decline: a novel therapeutic program. Aging (Albany NY). 2014 Sept; 6 (9) : 707-17.
215. Ellerby HM, **Bredesen DE,** Fujimura S, John V. Correction to hunter-killer peptide (HKP) for targeted therapy. J Med Chem. 2015 Feb 26; 58 (4) :2045.
216. Fiala M, Halder RC, Sagong B, Ross O, Sayre J, Porter V, **Bredesen DE**. ω-3 Supplementation increases amyloid-β phagocytosis and resolvin D1 in patients with minor cognitive impairment. FASEB J. 2015 Jul; 29 (7):2681-9.
217. Kurakin A, **Bredesen DE.** Dynamic self-guiding analysis of Alzheimer's disease. Oncotarget. 2015 Jun 10; 6 (16):14092-122.
218. Raji CA, Eyre H, Wei SH, **Bredesen DE**, Moylan S, Law M, Small G, Thompson PM, Friedlander RM, Silverman DH, Baune BT, Hoang TA, Salamon N, Toga AW, Vernooij MW. Hot Topics in Research: Preventive Neuroradiology in Brain Aging and Cognitive Decline. AJNR Am J Neuroradiol. 2015 Oct; 36 (10) :1803-9.
219. **Bredesen DE**. Metabolic profiling distinguishes three subtypes of Alzheimer's disease. Aging (Albany NY). 2015 Aug; 7 (8) : 595-600.
220. Peters-Libeu C, Campagna J, Mitsumori M, Poksay KS, Spilman P, Sabogal A, **Bredesen DE**, John V. sAβPPα is a Potent Endogenous Inhibitor of BACE1. J Alzheimers Dis. 2015; 47(3) : 545-55.
221. Zhang Q, Du G, John V, Kapahi P, **Bredesen DE**. Alzheimer's Model Develops Early ADHD Syndrome. J Neurol Neurophysiol. 2015; 6 (6) : 1-6.
222. Theendakara V, Peters-Libeu CA, Spilman P, Poksay KS, **Bredesen DE**, Rao RV. Direct Transcriptional Effects of Apolipoprotein E. J Neurosci. 2016 Jan 20; 36 (3) : 685-700.
223. **Bredesen DE**. Inhalational Alzheimer's disease: an unrecognized - and treatable - epidemic. Aging (Albany NY). 2016 Feb; 8 (2) : 304-13.
224. Spilman PR, Corset V, Gorostiza O, Poksay KS, Galvan V, Zhang J, Rao R, Peters-Libeu C, Vincelette J, McGeehan A, Dvorak-Ewell M, Beyer J, Campagna J, Bankiewicz K, Mehlen P, John V, **Bredesen DE**. Netrin-1 Interrupts Amyloid-β Amplification, Increases sAβPPα in vitro and in vivo, and Improves Cognition in a Mouse Model of Alzheimer's Disease. J Alzheimers Dis. 2016 Mar 8; 52 (1) :223-42.
225. **Bredesen DE**, Amos EC, Canick J, Ackerley M, Raji C, Fiala M, Ahdidan J. Reversal of cognitive decline in Alzheimer's disease. Aging (Albany NY). 2016 Jun; 8 (6) :1250-8.
226. Famenini S, Rigali EA, Olivera-Perez HM, Dang J, Chang MT, Halder R, Rao RV, Pellegrini M, Porter V, **Bredesen D**, Fiala M. Increased intermediate M1-M2 macrophage polarization and improved cognition in mild cognitive impairment patients on ω-3 supplementation. FASEB J. 2017 Jan; 31 (1) :148-160.
227. **Bredesen DE**, Rao RV. Ayurvedic Profiling of Alzheimer's Disease. Altern Ther Health Med. 2017 May; 23 (3) :46-50.

228. Poksay KS, Sheffler DJ, Spilman P, Campagna J, Jagodzinska B, Descamps O, Gorostiza O, Matalis A, Mullenix M, **Bredesen DE**, Cosford ND, John V. Screening for Small Molecule Inhibitors of Statin-Induced APP C-terminal Toxic Fragment Production. Front Pharmacol. 2017 Feb 15; 8:46.
229. Theendakara V, **Bredesen DE**, Rao RV. Downregulation of protein phosphatase 2A by apolipoprotein E: Implications for Alzheimer's disease. Mol Cell Neurosci. 2017 Sep; 83 : 83-91.
230. Theendakara V, Peters-Libeu CA, **Bredesen DE**, Rao RV. Transcriptional Effects of ApoE4: Relevance to Alzheimer's Disease. Mol Neurobiol. 2017 Sep 6.

B. COMMENTARY ON THE WORK OF THE BREDESEN LABORATORY

1. Marx J. Mutant enzyme provides new insights into the cause of ALS. *Science* 1996;**271**:446-447.
2. Ratel H. Quand la cellule se fait hara-kiri. *Sciences et Avenir* 2001;**648**:
3. Wyllie AH and Golstein P. More than one way to go. *Proc Natl Acad Sci U S A* 2001;**98**:11-13.
4. Fearon ER and Cho KR. Cancer: cell survival guide. *Nature* 2004;**431**:35-36.
5. Ellerby LM and Orr HT. Neurodegenerative disease: cut to the chase. *Nature* 2006;**442**:641-642.

C. BOOKS

1. Rosenblum ML, Levy RM and **Bredesen DE**. (1988) *AIDS and the Nervous System*. Raven Press, New York.
2. Simpson K and **Bredesen DE**. (2006) *The Perimenopause & Menopause: A Comprehensive Personalized Guide to Hormone Health for Women*. New Harbinger Publications, Inc., Oakland, CA.
3. Roninson IB, Brown MJ and **Bredesen DE**. (2008) *Beyond Apoptosis: Cellular Outcomes of Cancer Therapy*. Informa Healthcare, New York.
4. **Bredesen DE,** Rao RV**,** Mehlen P. (2007) *Programmed Cell Death and Its Role in Neurological Disease*, 125-144; In: Waxman SG, Ed. *Molecular Neurology*: Elsevier Academic Press

D. CHAPTERS

1. **Bredesen DE**, Levy RM and Rosenblum ML. (1987) Neurologic Complications of AIDS. In *AIDS: Diagnosis and Treatment*. BRS Saunders.

2. **Bredesen DE**. (1988) Implications of AIDS for neurological pathophysiology. Rosenblum, M.L., Levy, R.M. and **Bredesen , D.E**. (eds.), *AIDS and the Nervous System*. Raven Press, New York, NY.
3. Dix RD and **Bredesen DE**. (1988) Opportunistic viral infections in AIDS. In Rosenblum, M.L., Levy, R.M. and **Bredesen, D.E**. (eds.), *AIDS and the Nervous System*. Raven Press, New York, NY.
4. Levy RM and **Bredesen DE**. (1988) Central nervous system dysfunction in AIDS. In Rosenblum, M.L., Levy, R.M. and **Bredesen, D.E**. (eds.), *AIDS and the Nervous System*. Raven Press, New York, NY.
5. Levy RM, B**redesen DE** and Rosenblum ML. (1988) Overview of AIDS and the nervous system. In Rosenblum, M.L., Levy, R.M. and Bredesen, D.E. (eds.), *AIDS and the Nervous System*. Raven Press, New York, NY.
6. Levy RM, **Bredesen DE**, Rosenblum ML and Davis RL. (1988) Central nervous system disoders in the acquired immunodeficiency syndrome. In Levy, J.A. (ed.), *AIDS: Pathogenesis and Treatment*. Marcel Dekker, New York, Vol. **44**, pp. 371-401.
7. Miller RG, Kiprov DD, Parry GJ and **Bredesen DE**. (1988) Peripheral nervous system dysfunction in AIDS. In Rosenblum, M.L., Levy, R.M. and Bredesen, D.E. (eds.), *AIDS and the Nervous System*. Raven Press, New York, NY, p. 65.
8. Rosenblum ML, **Bredesen DE** and Levy RM. (1988) Algorithms for the treatment of AIDS patients with neurological disease. Rosenblum, M.L., Levy, R.M. and **Bredesen, D.E**. (eds.), *AIDS and the Nervous System*. Raven Press, New York, NY.
9. **Bredesen DE**, Levy RM and Rosenblum ML. (1989) Human immunodeficiency virus related neurological diseases. In Aminoff, M.J. (ed.), *Neurology and General Medicine*. Churchill-Livingstone, New York.
10. Levy RM and **Bredesen DE**. (1989) Controversies in HIV-related central nervous system disease: neuropsychological aspects of HIV-1 infection. In Volberding, P.A. and Jacobsen, M. (eds.), *AIDS 1988: Clinical Review*, New York, pp. 151-191.
11. Levy RM, **Bredesen DE** and Rosenblum ML. (1989) Neurologic disease in the acquired immunodeficiency syndrome (AIDS). In Leoung, G.S. and Mills, J. (eds.), *Opportunistic infections in patients with the acquired immunodeficiency syndrome*. Marcel Dekker, New York.
12. Prusiner SB, Hsiao KK, **Bredesen DE** and DeArmond SJ. (1989) Prion diseases of the nervous system. In Vinken, P.J., Bruyn, G.W., Klawans, H.L. and McKendall, R.R. (eds.), *Handbook of Clinical Neurology*. Elsevier, Amsterdam
13. Prusiner SB, Hsiao KK, **Bredesen DE** and Kingsbury DT. (1989) Human slow infections caused by prions. In Gilden, D.H. and Lipton, H.L. (eds.), *Clinical and Molecular Aspects of Neurotropic Virus Infection*. Kluwer Academic Publishers, Norwell.
14. **Bredesen DE**, Kane DJ, Holtzman DM and Epstein CJ. (1992) Preliminary characterization of reaggregating cultures of trisomy 16 central nervous system. In Epstein, C.J. (ed.), *Down Syndrome and Alzheimer Disease*. Wiley-Liss, Inc., New York, pp. 259-270.
15. Kordower JH, Schueler S, **Bredesen DE**, Freeman TB and Sagen J. (1993) Neural grafting for Parkinson's disease: an evaluation of dopaminergic donor tissues. In *Neural Transplantation, CNS Neuronal Injury/Regeneration*. CRC Press, Boca Raton.

16. **Bredesen DE**. (1994) Neuronal Apoptosis: Genetic and biochemical modulation. In *Apoptosis II: the molecular basis of apoptosis in disease*. Cold Spring Harbor Laboratory Press, pp. 397-421.
17. **Bredesen DE**. (1994) Neural apoptosis: genetic and biochemical modulation In Tomei, L.D. and Cope, F.O. (eds.), *Apoptosis II: The Molecular Basis of Apoptosis in Disease*. Cold Spring Harbor Laboratory, Plainview.
18. **Bredesen DE**. (1995) Modulation of cell death in neural cell lines and transplants. In Juurlink, B.H.J., Krone, P.H., Kulyk, W.M., Verge, V.M.K. and Doucette, J.R. (eds.), *Neural Cell Specification: Molecular Mechanisms and Neurotherapeutic Implication*. Plenum Publishing Corporation, New York.
19. **Bredesen DE**. (1996) Keeping neurons alive: the molecular control of apoptosis (part I). In *The Neuroscientist*. Williams & Wilkins, Baltimore, Vol. **2**, pp. 181-190.
20. **Bredesen DE**. (1996) Keeping neurons alive: the molecular control of apoptosis (part II). In *The Neuroscientist*. Williams & Wilkins, Baltimore, Vol. **2**, pp. 211-216.
21. Murphy AN, **Bredesen DE** and Fiskum G. (1996) Bcl-2 protection of mitochondrial function following chemical hypoxia/aglycemia. In Fiskum, E.G. (ed.), *Neurodegenerative Diseases: Molecular and Cellular Mechanisms and Therapeutic Advances*. Plenum Press, New York.
22. Murphy AN and **Bredesen DE**. (1997) Mitochondria, reactive oxygen species, and apoptosis. In Beal, M.F., Bodis-Wollner, I. and Howell, N. (eds.), *Mitochondria and Neurodegenerative Diseases: Mitochondria and Free Radicals in Pathogenesis.* . Wiley-Liss, New York.
23. Greenberg DA, Jin K, Galvan V and **Bredesen DE**. (2002) Neurogenesis and Alzheimer's disease. In Sun, M.-K. (ed.), *Research Progress in Alzheimer's Disease and Dementia*. Nova Science Publishers, New York, Vol. **1**, pp. 177-190.
24. Sperandio S, de Belle I, Castro-Obregon S, del Rio G and **Bredesen DE**. (2002) Cell death programs in neural development and disease. In Pak, C.H. (ed.), *Cerebrovascular Disease: 22nd Princteon Conference*. The Press Syndicate of the University of Cambridge, Cambridge, pp. 81-86.
25. Rao RV, Ellerby HM and **Bredesen DE**. (2004) Tumor Necrosis Factor (TNF) and Neurodegeneration. In Khare, S. (ed.), *The TNF Superfamily*. Landes Bioscience, Austin.
26. **Bredesen DE**, Rao RV and Mehlen P. (2007) Programmed Cell Death and Its Role in Neurological Disease. In Waxman, S. (ed.), *Molecular Neurology*. Elsevier Academic Press, Burlington, pp. 125-143.
27. **Bredesen DE**. (2008) Toward a Mechanistic Taxonomy for Programmed Cell Death Pathways. In Roninson, I.B., Brown, J.M. and **Bredesen, D.E**. (eds.), *Beyond Apoptosis: Cellular Outcomes of Cancer Therapy*. Informa Healthcare, New York, pp. 73-91.
28. Koo EH and **Bredesen DE**. (2008) Aβ-Induced Toxicity Mediated by Caspase Cleavage of the Amyloid Precursor Protein (APP). In Selkoe, D.J., Triller, A. and Christen, Y. (eds.), *Synaptic Plasticity and the Mechanism of Alzheimer's Disease.* . Springer-Verlag, Berlin Heidelberg, pp. 145-155.
29. **Bredesen DE**. (2010) BACE, APP Processing, and Signal Transduction in Alzheimer's Disease. John, V. (ed.), *BACE: Lead Target for Orchestrated Therapy of Alzheimer's Disease*. John Wiley & Sons, Inc., Hoboken, NJ, pp. 1-14.

30. **Bredesen DE**. Role of Programmed Cell Death in Neurodegenerative Disease. Reed, J.C. and Green, D. (eds.), *Apoptosis: Physiology and Pathology of Cell Death*. Cambridge University Press, New York.
31. **Bredesen, D.E**., Prionic Loops, Anti-Prions, and Dependence Receptors in Neurodegeneration, Prusiner Beitrag 2013

E. CHAPTERS – (IN PRESS)

32. Jagust W, **Bredesen, DE**, Campisi, JC, Lithgow, G, Vijg, J, *Molecular and Cellular Biology of Aging (*2013) *in press.*

F. ABSTRACTS

1. McCarty KS, Jr, **Bredesen DE**, Schomberg D, Kramer R and Hammond C. Effects of 2-bromoergocryptine on organ-cultured human prolactin-secreting microadenomas. 1977, *In Vitro*, **13**:189.
2. **Bredesen DE**, Cutler JR and Simon RP. Failure of naloxone to reverse vascular neurologic deficit. 1982, *Neurol*, **32**:A79.
3. Raskin NH, **Bredesen DE**, Ehrenfeld WK and Kerlan RK. Portal-systemic encephalopathy due to congenital extrahepatic shunt. 1982, *Neurol*, **32**:A80.
4. **Bredesen DE**, Lipkin WI and Messing RO. Prolonged, recurrent aseptic meningitis with prominent cranial nerve abnormalities--a new epidemic in gay men? 1983, *Neurol*, **33**:85.
5. **Bredesen DE** and Messing RO. Neurological syndromes heralding the acquired immune deficiency syndrome. 1983, *Ann Neurol*, **14**:141.
6. **Bredesen DE** and Parry GJ. Pyridoxine neuropathy. 1984, *Neurol*, **34(suppl 1)**:136.
7. Dix RD, **Bredesen DE,** Davis RL and Mills J. Spectrum of Herpes encephalitis in immunodeficient homosexual men: potential role of immune response. 1984, *Abstracts of the IX International Herpes Virus Workshop,* Seattle.
8. Dix RD, **Bredesen DE**, Davis RL and Mills J. Spectrum of Herpes encephalitis in homosexual men with persistent lymphadenopathy or AIDS. 1984, *Abstracts of the XXIV ICAAC and Infectious Disease Society of America,* Washington.
9. Levy RM, **Bredesen DE** and Rosenblum ML. Neurological manifestations of the acquired immunodeficiency syndrome: neurosurgical implications. 1984, *Congress of Neurological Surgeons Annual Meeting*.
10. Dix RD, **Bredesen DE**, Davis RL and Mills J. Herpes virus neurologic disease associated with AIDS: recovery of virus from CNS tissue, peripheral nerve, and CSF. 1985, *Abstracts International Conference on AIDS,* Atlanta.
11. Levy RM, **Bredesen DE**, Moore SG and Mills C. Cranial magnetic resonance imaging in the acquired immunodeficiency syndrome (AIDS): superiority to CT. 1985, *Abs IV Ann Mtg Soc Mag Res in Med*, London.
12. Levy RM, **Bredesen DE** and Rosenblum ML. Neurologic manifestations of AIDS. 1985, *Abs Intl Conf on AIDS,* Atlanta.

13. Levy RM, **Bredesen DE** and Rosenblum ML. Neurologic manifestations of AIDS; evaluation of 338 patients with AIDS or general lymphadenopathy. 1985, *Abs Amer Assoc Neurol Surg*.
14. Levy RM, **Bredesen DE** and Rosenblum ML. Multiple simultaneous intracranial pathologies in AIDS. 1985, *Abs Cong Neurol Surg Ann Mtg*.
15. **Bredesen DE**, Parry GJ, Koo EH and Davis RL. Cytomegalovirus neuropathy in AIDS. 1986, *Abs of the Intl Congress of Neuropath*, Stockholm326.
16. **Bredesen DE**, Scott M, Butler DA and Prusiner SB. Transient expression of hamster prion proteins in scrapie-infected murine cells. 1987, *Neurol*, **37(suppl)**:342.
17. Scott M, Borchelt D, **Bredesen DE**, Butler D, Hsiao K and Prusiner SB. Expression of the hamster PrP gene using eukaryotic expression vectors. 1987, *ANA, VII International Congress Virology*, 147.
18. **Bredesen DE**, Scott MRD, Torchia T and Prusiner SB. Differentiation modulates cellular prion protein expression and targeting. 1988, *J Cell Biol*, **107**:100a.
19. Engstrom J, Lowenstein DH and **Bredesen DE**. Cerebral infarctions and transient neurologic deficits associated with AIDS. 1988, *Neurol*, **38(suppl 1)**:241.
20. Graham S and **Bredesen DE**. Neurologic complications of herpes zoster in patients with HIV infection. 1988, *Neurol*, **38(suppl)**:120.
21. Stricker RB, **Bredesen DE**, Neyman P, Wesley AM and Mahawar SK. Autoimmunity in the pathogenesis of HIV-related peripheral neuropathy. 1988, *Retroviruses and Disease*, Heraklion, Crete, **September**.
22. **Bredesen DE**, Hisanaga K and Sharp FR. Neural transplantation with temperature-sensitive immortalized neural cells. 1989, *Neurol*, **39(supp 1)**:124.
23. **Bredesen DE**, Scott MRD, Torchia T and Prusiner SB. Differentiation modulates cellular prion protein expression and targeting. 1989, *Neurol*, **39 (supp 1)**:396.
24. **Bredesen DE**, Stricker RB, Neyman P, Wesley AM and Mahawar SK. Autoimmunity in the pathogenesis of HIV-related peripheral neuropathy. 1989, *Neurology*, **39 (supp 1)**:329.
25. **Bredesen DE**, Stricker RB, Neyman P, Wesley AM and Mahawar SK. Autoimmunity in the pathogenesis of HIV-related peripheral neuropathy. 1989, *Neurol*, **39 (supp 1)**:329.
26. Grohmann S, Levy R, **Bredesen DE,** Rosenblum M, Cohen B, Von Roenn J and Murphy R. AIDS-related neurological illness in two U.S. cities: a comparison of similar populations. 1989, *AIDS Meeting, ,* Montreal.
27. Koch T, Wesley MA, Koerper M, Lewis EM and **Bredesen DE**. Epidemiology of HIV-associated peripheral neuropathy. 1989, *AIDS Meeting*, Montreal.
28. Koch TK, Koerper MA, Wesley AM, Lewis EM, Weintrub PS and **Bredesen DE**. Absence of an AIDS-related peripheral neuropathy in children and young adult hemophiliacs. 1989, *Ann Neurol*, **26(3)**:476.
29. Levy R, Rosenblum M and **Bredesen DE**. Clinical findings in patients with AIDS-related neurologic illness: is their predictive value sufficient to defer biopsy? 1989, *AIDS Meeting*, Montreal.
30. Lewis EM, Mahawar SK, Wesley AM and **Bredesen DE**. The differential diagnosis of cranial neuropathy in AIDS patients. 1989, *AIDS Meeting*, Montreal.
31. Stricker RB, **Bredesen DE**, Wesley MA, Mahawar SK, Chernoff D and Hollander H. Autoimmunity in the pathogenesis of HIV-related peripheral neuropathy. 1989, *AIDS Meeting*, Montreal.

32. **Bredesen DE**, Seelig M, Yang J and Kedersha N. Immortalization and differentiation of mdx mouse myoblasts. 1990, *Society for Neuroscience Abstracts*, **16**:142.
33. **Bredesen DE**, Kane DJ, Holtzman DM and Epstein CJ. Reaggregating cultures of mouse trisomy 16 CNS. . 1991, *Society for Neuroscience Abstracts*, **17**:1064.
34. **Bredesen DE**, Kane DJ, Holtzman DM and Epstein CJ. Reaggregating cultures of mouse trisomy 16 brain. 1991, *Society for Neuroscience Abstracts*, **17**:1064.
35. **Bredesen DE**, Manaster J, Rayner S, Kane D and Markham C. Functional improvement in parkinsonism following transplantation of temperature-sensitive immortalized neural cells. 1991, *Neurology (suppl.)*, **4**:325.
36. Hisanaga K, **Bredesen DE** and Sharp FR. A central neuronal-like cell line immortalized with a retrovirus encoding the temperature-sensitive SV40 large T antigen. 1991, *Society for Neuroscience Abstracts*, **17**:32.
37. Verity AN, **Bredesen DE** and Campagnoni AT. Immortalization of normal mouse and shiverer oligodendrocytes. 1991, *International Society for Neurochemistry*.
38. Anton R, Kordower JH, Manaster J, Melega W, Markham CH and **Bredesen DE**. Neural-targeted gene therapy for rodent and primate hemiparkinsonism. 1992, *IV International Symposium on Neural Transplantation*, Washington, D.C.
39. Anton R, Manaster J, Kordower JH, Markham CH and **Bredesen DE.** Neural-directed gene therapy for a Parkinson's disease animal model. . 1992, *Neurology*, **42(suppl 3):** :379.
40. Kordower JH, schueler SB, Markham CH, Melega W, Anton R and **Bredesen DE**. Temperature-sensitive substantia nigra neural cells for CNS transplantation: in vitro analysis and grafting into parkinsonian rats and monkeys. 1992, *Society for Neuroscience Abstracts*, **18:782**:782.
41. Zhong LT, Mah SP, Edwards RH and **Bredesen DE**. Bcl-2 inhibits apoptosis in multiple neural cell types. 1992, *Society for Neuroscience Abstracts*, **18**:44.
42. Anton R, Kane DJ, Manaster JS, Kordower JH, Schueller SB, Markham CH and **Bredesen DE**. Use of the anti-apoptotic gene bcl-2 in neural transplantation. 1993, *Society for Neuroscience Abstracts*, **19**:1053.
43. **Bredesen DE**, Kane DJ, Rabizadeh S, Anton R, Huang TT, Epstein CJ and Sarafian TA. The mechanism by which BCL2 inhibits neural cell death. 1993, *Biol Oxidants and Antioxidants Abs*, Biol Oxidants and Antioxidants Abs 1993:1952.
44. Kane DJ, Sarafian TA, Anton R and **Bredesen DE**. BCL-2 inhibits neural cell death by decreasing the production of reactive oxygen species. 1993, *Society for Neuroscience Abstracts*, **19**:671.
45. Rabizadeh S, Friesen PD and **Bredesen DE**. Neural apoptosis is inhibited by the baculovirus p35 gene. 1993, *Neurol*, **43 (suppl 2)**:A299.
46. Murphy AN, Myers KM, **Bredesen DE** and Fiskum G. Bcl-2 protects neuronal cells from hypoxia/reoxygenation induced death. 1994, *Society of Neuroscience Abstracts*, **20**:425-426.
47. Schueller SB, **Bredesen DE**, Anton R, Carvey PM and Kordower JH. BDNF-transfected oligodendrocytes increase dopaminergic fetal nigral neuron survival and enhance neuritic extension in vitro. 1994, *Society for Neuroscience Abstracts*, **20**:454.454.
48. Marshall K, Ellerby LM, Wang H-G, Reed JC, **Bredesen DE**, Aruoma OI and Halliwell B. Possible antioxidant action of the Bcl-2 protein. 1995, *The Oxygen Society*.

49. Murphy AN, **Bredesen DE** and Fiskum G. Bcl-2 protects neural cell mitochondria from Ca2+ overload and Ca2+-induced respiratory inhibition. 1995, *Society for Neuroscience Abstracts*, **21(3)**:1728.
50. Perry DC, Wei H, Wei W and **Bredesen DE**. Bcl-2 inhibits apoptosis induced by thapsigargin or caffeine in GT1-7 neuronal cells. 1995, *Society for Neuroscience Abstracts*, **21(2)**:1518.
51. Wei H, Perry DC, Wei W and **Bredesen DE**. Dantrolene inhibits neuronal death in vivo after cerebral ischemia and in vitro after thapsigargin or caffeine. 1995, *Society for Neuroscience Abstracts*, **21(1)**:217.
52. Yeo TT, Kunimitsu JH, **Bredesen DE** and Butcher LL. Cholinergic neurons in transgenic mice with an altered low-affinity NGFr gene. 1995, *Society for Neuroscience Abstracts*, **21(2)**:1551.
53. Zhong LT, Noterpek L, Oh J, ruan YL, Butcher L, Faull KF, Fluharty AL and **Bredesen DE**. A monoclonal antibody that induces apoptosis in neocortical neurons binds to a novel class of death receptor. 1995, *Society for Neuroscience Abstracts*, **21(3)**:2020.
54. Kruman I, Guo Q, Bruce-Keller AJ, **Bredesen DE** and Mattson MP. Hydroxynonenal may mediate apoptotic neuronal death induced by trophic factor withdrawal and oxidative insults. . 1996, *Society for Neuroscience Abstracts*, **22(2)**:1481.
55. Murphy AN, Mootha V, **Bredesen DE** and Fiskum G. Effects of Bcl-2 on mitochondrial Ca2+ uptake and proteolytic activity. 1996, *Society for Neuroscience Abstracts*, **22(2)**:1178.
56. Sloan A, Bandong J, Hedricks L, Vinters H, **Bredesen DE** and Black K. BCL-2 expression as a prognostic indicator in low grade astrocytomas: Induced BCL-2 expression inhibits apoptotic response to chemotherapy and radiation, and is associated with poor prognosis. 1996, *Congress of Neurological Surgeons*.
57. Yeo TT, Longo FM, **Bredesen DE** and Butcher LL. Dependence of cholinergic innervation of the limbic system on p75 NGF receptor. 1996, *Society for Neuroscience Abstracts*, **22**:1008.
58. **Bredesen DE**. Post-mitotic cells: ALS, neurodegeneration. 1997, *American Society of Biochemistry and Molecular Biology Abstracts,* A1449.
59. Butcher LL, Longo FM, Kunimitsu JH, **Bredesen DE** and Yeo TT. β-amyloid peptide is neurotoxic to basal forebrain but not to striatal cholinergic neurons. 1997, *Society for Neuroscience Abstracts*, **23(2)**.
60. Hackam AS, Ellerby LM, Wellington CL, **Bredesen DE** and Hayden MR. Development of an in vitro model for Huntington's Disease. 1997, *American Society of Human Genetics*.
61. Jurgensmeier JM, Ellerby L, Xie Z, **Bredesen DE** and Reed JC. Bax induces mitochondrial permeability transition and release of cytochrome c. 1997, *ESH-ECDO Fifth Euroconference on Apotosis*, Bingen/Rhein, Germany, **October**.
62. Rabizadeh S, Ye X, Sperandio S, Fukuda S and **Bredesen DE**. A neurotrophin dependence domain within p75NTR. 1997, *Society for Neuroscience Abstracts*, **23(1)**:337.
63. Yeo TT, Chua-Couzens J, Valletta JS, **Bredesen DE**, Mobley WC and Longo FM. Absence of p75NTR causes neuronal hypertrophy and increased target innervation of the basal forebrain in cholinergic neurons. 1997, *Society for Neuroscience Abstracts*, **23(1)**:335.
64. Tasinato A, Fukuda S, Rabizadeh S and **Bredesen DE**. A novel domain in the p75NTR that confers neurotrophin dependence. 1998, *USGEB98 Meeting*.

65. Castro-Obregon S, Chen SF, Del Rio G, Swanson RA and **Bredesen DE**. NK1R is a novel type of death receptor, inducing a non-apoptotic form of programmed cell death. 2001, *Society for Neuroscience Abstracts*.
66. Del Rio G, Castro-Obregon S, Rao RV, Ellerby HM and **Bredesen DE**. APAP, a sequence-pattern recognition approach to design pro-apoptotic peptides. 2001, *Society for Neuroscience Abstracts*.
67. Hermel E, Del Rio G, **Bredesen DE** and Ellerby LM. Molecular evolution of the caspase gene family. 2001, *FASEB*.
68. Sperandio S, Stoka V, Poksay K, Cottrell B and **Bredesen DE**. A proteomic approach to the characterization of non-apoptotic programmed cell death. 2001, *Society for Neuroscience Abstracts*.
69. Galvan V, Saganich M, Schroeder B, Gorostiza OF, Logvinova A, Banwait S, Jin K, Greenberg DA, Mucke L, Heinemann S, Koo EH and **Bredesen DE**. Reversal of AD - like pathology in APP transgenic mice by mutation of ASP664. 2004, *Society for Neuroscience Abstracts*, San Diego, CA.
70. Schroeder B, Saganich M, Galvan V, Long JM, **Bredesen DE**, Heinemann S and Koo EH. The importance of caspase cleavage of the cytoplasmic domain of amyloid precursor protein (APP) in the behavioral and synaptic transmission deficits of APP transgenic mice. 2004, *Society for Neuroscience Abstracts*, San Diego, CA.
71. **Bredesen DE**. Apoptosis versus alternative cell death programs. 2005, *Proc Amer Assoc Cancer Res Abstracts* **46**.
72. Peters-Libeu C, Poksay K, Corset V, **Bredesen DE** and John V. Amyloid Precursor Protein (app)-mediated Signal Transduction: 3d-Structural Studies Toward the Development of Novel Therapeutic Agents for AD. 2008, *International Conference on Alzheimer's Disease abstracts*, Chicago, Illinois.
73. Zhang J, Swistowski A, Orcholski M, Kurakin A, **Bredesen DE** - Novel downstream mediators of APP signalling 2009 *Int'l Conference on Alzheimer's Disease abstracts*, Vienna, Austria
74. Descamps O, Zhang J, John V, **Bredesen DE** Modulation of the Intracellular Proteolytic Cleavage of APP by Statins - 2011 *Alzheimer's Assn., Int'l Conf. on Alzheimer's Disease abstracts*, Paris, France
75. John V, Spilman P, Descamps O, Poksay K, **Bredesen DE** "Switching" Drugs: Candidate Therapeutics That Switch APP Processing From Anti-Trophic to Trophic, In Vitro and In Vivo - 2011 *Alzheimer's Assn., Int'l Conf. on Alzheimer's Disease abstracts* Paris, France
76. Corset V, Peters-Libeu C, Spilman P, Poksay K, Descamps O, Gorostiza O, John V, Mehlen P, **Bredesen DE** - Novel Prionic and Anti-Prionic Mechanisms in Alzheimer's Disease 2011 *Alzheimer's Assn., Int'l Conf. on Alzheimer's Disease abstract*, Paris, France